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Abstract 
Prostate cancer is one of the most common cancers in the Western world. The 
metastasis of prostate cancer cells is the major cause of prostate cancer-related death. 
Understanding which genes are altered in prostate cancer and their implications for cell 
signaling and function is crucial for designing therapy strategies. Our group has identified 
a high frequency of somatic missense mutations in the plexin-B1 gene in localized and 
metastatic prostate cancer. The mutations are correlated with elevated metastatic features 
such as increased cell invasion, adhesion and decreased cell collapse relative to wildtype. 
Given the fact  that  Sema4D/plexin-B1 regulates  cell signaling through coupling with 
tyrosine  kinases  and  small  GTPases,  I  hypothesized  that  plexin-B1  mutations  may 
contribute to prostate cancer cell progression through affecting these pathways. The aims 
of this study were to characterize the molecular features of the three mutated forms of 
plexin-B1, A5359G, A5653G, and T5714C and to determine how the mutations affect 
cell signaling. It was found, using co-immunoprecipitation assays, that none of the three 
mutations affected the binding of either ErbB-2 or Met to plexin-B1. Sema4D/plexin-B1 
mediated cell motility depending on the stoichiometry of plexin-B1, ErbB-2 and Met in 
prostate cancer cells. In addition, positive evidence was found for the impact of wildtype 
and mutant plexin-B1 on PI3K/Akt and MAPK pathways. All the three mutants exhibited 
an  increased  binding  ability  to  RhoD  GTPase  relative  to  wildtype  in  GST-pulldown 
assays. This increased binding to RhoD is also associated with increased cell motility as 
shown in transwell migration assays. My study suggests that the three mutants confer a 
gain of metastatic phenotype to the cells through inactivating inhibitory pathways and has 
lead to the construction of a new model describing the mechanism by which plexin-B1 
mutations contribute to cancer progression. 6 
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Chapter 1 
Introduction 16 
 
1.1 Prostate cancer 
1.1.1 The prostate 
1.1.1.1 General features of the prostate 
The prostate gland is part of the male reproductive system that helps make and 
store seminal  fluid.  It  functions  to  store and secret  a lightly alkaline fluid  that helps 
neutralize the acidity of the vaginal tract, prolonging the lifespan of sperm. The prostate 
is  a  ductal-acinar  exocrine  gland  that  develops  from  the  urogenital  sinus.  The 
development of the gland begins in fetal life and is completed at sexual maturity. It is 
located under the urinary bladder and in front of the rectum in the pelvis (Figure 1.1). The 
prostate surrounds part of the urethra that carries urine from the bladder during urination 
and  semen  during  ejaculation.  The  mature  human  prostate  is  typically  around  3 
centimeters  long  and  weights  about  twenty  grams.  Human  prostate  is  divided 
anatomically  into  the  non-glandular  fibromuscular  stroma  which  permeates  and 
surrounds  the  organ  and  three  glandular  regions  termed  central,  peripheral,  and 
transitional zones (Figure 1.2) (McNeal, 1983a; McNeal, 1983b). The peripheral zone is 
the largest region and is the principal site of prostatitis and carcinoma of the prostate 
(McNeal,  1969).  The  transitional  zone  consists  of  two  small  lobes  surrounding  the 
prostatic  urethra,  with  ducts  opening  to  the  prostatic  urethra.  Prostate  cancer  rarely 
develops  within  the  transitional  zone.  However,  the  transitional  zone  is  the  site  of 
development of benign prostate hyperplasia (BPH) (McNeal, 1983a). The central zone 
surrounding  the  ejaculatory  ducts  is  conical  shaped;  its  ducts  empty  into  the  urethra 
proximal to the verumontanum. The central zone is virtually disease-free. 17 
 
 
Figure 1.1 The prostate and surrounding organs. This figure illustrates
the inside anatomy of the male pelvis. The prostate is below the bladder
and surrounding urethra. The picture is adapted from the National Cancer
Institute under the topic of prostate cancer (http://www.cancer.gov).
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Figure 1.2 Zones of the prostate. This figure shows the four distinct
glandular regions. The peripheral zone is the largest region, from which
region more than 60% of prostatic cancer originates. The central zone
surrounds the ejaculatory ducts and cancer from the central zone tends to be
more aggressive. The transitional zone consists of two small lobes
surrounding the prostatic urethra. The anterior zone is mainly composed of
fibroblast and muscle tissues. This picture is adapted from the National
Cancer Institute under the topic of prostate anatomy
(http://training.seer.cancer.gov/prostate).
TZ 20%
U
CZ 5-8%
PZ 75%
U Urethra
TZ Transitional zone
CZ Central zone
PZ Peripheral zone
Fibromuscular 
stroma
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1.1.1.2 Role of androgens during prostate development 
  Development  of  the  prostate  is  dependent  on  reciprocal  interactions  between 
mesenchyme and epithelium, as well as on androgens. During the embryonic stage of 
prostate  gland  development,  androgen  receptors  (ARs)  are  detected  in  the  urogenital 
sinus mesenchyme while the epithelium  is  initially AR-negative  (Cooke et  al.,  1991; 
Takeda  and  Chang,  1991).  Androgen  receptors  are  detectable  in  developing  prostatic 
epithelium shortly after birth in both mouse and rats (Moeller et al., 1987; Prins and 
Birch,  1995).  Cunha  and  his  colleagues  performed  tissue  combination  studies  using 
wildtype  and  AR-negative  testicular  feminization  mice  (tfm)  to  elucidate  the  role  of 
androgen  receptors  in  both  mesenchyme  and  epithelium  during  prostate  development 
(Cunha and Young, 1991a) . Wildtype mesenchyme is able to induce normal prostatic 
morphogenesis when combined with either wildtype epithelium or tfm epithelium from 
urogenital sinus (Cunha et al., 1992a; Cunha et al., 1992b). However, tfm mesenchyme 
fails  to  stimulate  the  prostate  gland  development  when  in  combination  with  either 
wildtype  or  tfm  epithelium.  These  findings  indicate  that  the  presence  of  androgen 
receptors in the mesenchyme is crucial in the morphogenesis and development of the 
epithelium of the prostate. Cunha et al. further revealed the role of ARs on epithelial cells. 
The combination of wildtype mesenchyme and wildtype epithelium from urogenital sinus 
gives  rise  to  a  functional  prostatic  gland  that  produces  secretory  proteins.  The 
combination  of  wildtype  mesenchyme  with  tfm  epithelium  though  could  stimulate 
development of the prostatic phenotype, but failed to express prostatic secretory proteins 
(Cunha and Young, 1991b; Donjacour and Cunha, 1993). These findings indicate that 20 
 
epithelial ARs are necessary for the production of prostatic secretary proteins, but are not 
essential for prostatic morphogenesis. 
 
1.1.2 Prostate cancer 
 1.1.2.1 Overview of prostate cancer  
Prostate cancer is  the malignancy of the prostate gland.  It is a common male 
disease across the world, with more than 670,000 men diagnosed with prostate cancer 
each year worldwide. The highest rates of detection are in Europe and the United States 
whilst lower frequencies are in South and East Asia. In the UK, prostate cancer is the 
most  common  cancer  in  men  and  accounts  for  nearly  24%  of  all  new  male  cancer 
diagnoses. In 2006, there were 35,515 new cases of prostate cancer diagnosed in UK 
(data from Cancer Research UK). In the past 30 years the incidence of prostate cancer has 
tripled, however, much of the increase is largely due to the widespread use of prostate-
specific antigen (PSA) testing since 1986 (Welch and Albertsen, 2009). Prostate cancer is 
the second most common cause of cancer death in UK men. It is estimated that each year 
around 10, 200 men in the UK die from this disease. 
  Majority of prostate cancer cases are adenocarcinoma consisting of epithelial cells 
and  70%  of  all  prostatic  adenocarcinoma  arises  from  peripheral  zone  of  the  prostate 
(McNeal et al., 1988). Compared to normal prostate, prostate cancer is characterised by 
irregular glands and clumps of cells. Prostate cancer progresses from an early, androgen-
dependent, localized disease to advanced, androgen-independent, metastatic disease. The 21 
 
localized or early metastatic disease can be effectively treated with radical prostatectomy 
or androgen-deprivation therapy (Westin et al., 1995). However, approximately 18-24 
months after the start of therapy, the tumor may eventually recur and becomes hormone-
refractory and more aggressive (Santen, 1992). At this stage of the disease, chemotherapy 
is one of the options for controlling tumor progression. There are currently no effective 
cytotoxic  chemotherapeutic  agents  available  for  effective  control  and  improving  the 
survival of patients with hormone-refractory disease. 
 
1.1.2.2 Prostate cancer development 
  Prostate  cancer  is  the  main  type  of  prostatic  disease  in  adult  males.  Prostate 
cancer tends to develop in men above the age of 50. With increasing age, the incidence of 
prostate  cancer  increases.  Approximately  75%  of  the  clinically  diagnosed  prostate 
cancers are in men between the ages of 50-70 years old (Brawley et al., 1998). In fact, 
most men display signs of prostate malignancy at some time point during their lifetime. 
Although prostate cancer is one of the most prevalent types of cancer in men, many never 
exhibit symptoms or may eventually die with prostate cancer but not from this disease. 
This is because cancer of prostate is a slow growing cancer in most cases. Early prostate 
cancer usually causes no symptoms. However, prostate cancer does cause symptoms at a 
later stage. It is associated with urinary dysfunction as the prostate gland surrounds the 
prostatic urethra, causing frequent urination and painful urination. Once prostate cancer 
develops from the organ-confined disease to the metastatic disease, tumor cells become 
highly invasive and spread to distant organs. The main sites of metastasis of prostate 22 
 
cancer are the regional lymph nodes and the bone system. Approximately 70% of the 
prostate cancer patients die of this disease with metastatic disease in their bone (Zetter, 
1990). The most common symptom is bone pain. 
  Prostate  cancer  is  graded  by  using  Gleason’s  grading  system  based  on  the 
histological tumor patterns clinically. Together with other parameters, Gleason’s grading 
system predicts prognosis and helps guide therapy. Figure 1.3 illustrates the patterns of 
Gleason’s  grading  system.  High-grade  prostatic  intraepithelial  neoplasis  (PIN)  is 
considered as the most likely precursor of adenocarcinoma (McNeal and Bostwick, 1986). 
It arises by proliferation of the luminal epithelium in the peripheral and transition zone of 
the prostate (De Marzo et al., 1998). After a period of time, prostate cancer becomes very 
heterogeneous. Gleason’s grading system is used to assess the complexity of prostate 
cancer (Gleason, 1977). The pathologist assigns the most common tumor pattern and the 
next most common tumor pattern each a grade. The score is the sum of the two dominant 
grades by area, e.g. 4 + 5 = 9. Generally more advanced prostatic adenocarcinoma is 
correlated with a higher Gleason score (Gleason, 1992). Prostate cancer is the result of 
the accumulation of mutations and other genetic alterations occurring in prostate cells. 
Significant genetic changes within the prostate tumor cells have been observed to be 
associated with their pathological malignancy (Konishi et al., 1995; Ruijter et al., 1999; 
Sakr et al., 1994). 
 
 23 
 
Figure 1.3. Schematic diagram representing the Gleason grading
system. Gleason score is the sum of the two dominant grades by area. This
picture is adapted from the book Urologic Pathology: The Prostate under
the topic of Histologic grading and clinical staging of prostatic carcinoma
(Gleason, 1977).
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1.1.2.3 Genetic alterations associated with prostate cancer 
  Prostate  carcinogenesis  is  a  multi-step  process  that  consists  of  initiation, 
proliferation,  invasion  and  metastasis.  This  process  is  characterized  by  multiple 
aberrantly regulated pathways. At the molecular levels, the aberrant activities of these 
pathways result from the activation of oncogenes or inactivation of the tumor suppressor 
genes. Oncogenes are derived from proto-oncogenes that are oncogenic through genetic 
alterations  such  as  mutation,  partial  deletion,  rearrangement,  over-expression  and 
amplification  of  genes,  leading  to  abnormal  cell  growth  and  proliferation.  In 
haematological  malignancies  oncogene  mutations  predominate,  however,  like  other 
epithelial tumourigenesis very few oncogenes have been defined in prostate tumor. Over-
expressions of ErbB-2, myc, Bcl-2 have been reported to be correlated with advanced 
prostate cancer progression (Ross et al., 1993; Rosser et al., 2003; Sato et al., 1999). The 
exhibition of neoplastic phenotype in prostate cancer is a progressive and cumulative 
result of altered genotype. This process involves modifications in tumor suppressor genes 
such  as  deletion,  mutations,  rearrangement  or  methylation.  Tumor  suppressor  gene 
inactivation  is  associated with  tumor formation  and progression of advanced prostate 
cancer. Several tumor suppressor genes have been identified and found to be mutated in 
advanced prostate cancer, but infrequently altered in early prostatic disease. For example, 
mutations of p53 gene in advanced stage of prostate cancer is higher in frequency than 
that  in  primary  prostate  tumors  (Bookstein  et  al.,  1993;  Navone  et  al.,  1999). 
Approximately 50% of advanced prostate tumors show PTEN mutations (Feilotter et al., 
1998). 25 
 
1.1.2.4 Risk factors 
  Although the specific causes of prostate cancer remain unclear, it is found that 
development of prostate cancer is associated with numerous factors such as age, race, 
dietary and environmental factors, steroid hormones, and family history. However, aging 
is the most important risk factor in prostate cancer development. 
 
1.1.2.5 Treatment of prostate cancer 
  Up to now there is actually no best treatment for prostate cancer. Conventionally, 
treatment options depend on the stage of the disease at diagnosis, the Gleason score, and 
the PSA level. Other factors are the man’s age and his general health. For patients with 
primary  or  organ-confined  disease,  radiotherapy  or  surgery  is  applicable,  whereas 
hormone therapy is the standard treatment option for patients with metastatic disease. 
However,  almost  all  patients  with  metastatic  prostatic  disease  will  finally  become 
hormone unresponsive and refractory to hormone treatment. Chemotherapeutic agents 
have  been  developed  recently;  however,  most  of  the  chemotherapeutic  options  are 
palliative and cannot improve the survival of patients with advanced disease. 
  Watchful waiting or active surveillance is a concept in which the patient avoids 
active  treatment  but  the  disease  is  monitored  by  estimating  the  PSA  at  several  time 
intervals. It is estimated that 50-80% of the prostate cancer patients will not become 
symptomatic even with no treatment (Yao and Lu-Yao, 2002). In some patients localized 
disease will not progress during their life time. The active surveillance is also applicable 26 
 
for patients who have a life expectancy of less than 10 years. Due to the development of 
PSA screening, the majority of patients with prostate cancer are diagnosed at the stage of 
regional or localized disease. Radical  prostatectomy is  ideal  for patients  who present 
early, curable disease detected by the  PSA test.  It  is  also  important  that  the patients 
should be under  good  healthy  conditions  to  take the surgery. The life  expectancy of 
patients should be at least 10 years after surgery so that patients can benefit from surgery. 
Radiotherapy is the most commonly used curative treatment for both early and locally 
advanced prostate cancer patients (Dearnaley, 1995). It is a treatment which kills cancer 
cells or inhibits cellular division of cancer cells using ionizing radiation (high-energy x-
rays) without significant damage to the surrounding normal tissues. There are a number 
of irradiation methods for prostate cancer including brachytherapy, the most commonly 
used radiotherapy. Bracheytherapy is the method in which the radiation source is placed 
close to or within the prostate cancer area. The overall survival rates were 96% and 86% 
for 5- and 10-year disease specific survival rate respectively from the Radiation Therapy 
Oncology Group (RTOG) 77-06 study (Hanks et al., 1991). The local recurrence rates of 
5- and 10-year were 4 and 13%, respectively. Radiotherapy is one of the ideal treatments 
for patients with advanced local disease. 
  For patients undergoing radical prostatectomy or radiotherapy, the actuarial 10-
year likelihood of biochemical disease recurrence is approximately 25%  (Coen et al., 
2002;  Han  et  al.,  2001).  Among  the  prostate  cancer  25-30%  of  the  tumors  behave 
aggressively (Parker et al., 1996). For patients who develop metastatic prostate cancer or 
those initially present advanced disease, ablation of androgen therapy is regarded as the 
optimal first-line treatment for advanced prostate cancer (Chodak et al., 2002). Initially 27 
 
approximately  70-80%  of  the  patients  respond  to  androgen-depletion  therapy  with  a 
remarkable reduction of androgen-responsive cancer cells (Gittes, 1991). However, after 
a median duration of 18-24 months, almost all tumors become hormone-refractory and 
more  aggressive.  Side-effects  of  androgen-depletion  therapy  include  hot  flushes  and 
sexual  problems.  Over  the  last  decade,  much  improvement  has  been  made  in  the 
treatment  of hormone-refractory  prostate cancer. Chemotherapy is one  of the options 
available. Historically, mitoxantrone is used as the most active chemotherapeutic agents 
that could ameliorate symptoms but do not show a provable effect on improving survival. 
The median duration of survival is 12.3 months on mitoxantrone (Tannock et al., 1996). 
More  recently  a  new  therapeutic  alternative,  docetaxel-based  chemotherapy  has 
demonstrated a survival advantage compared to mitoxantrone-based therapy when used 
in patients with metastatic hormone-refractory prostate cancer (Tannock et al., 2004). 
Patients with docetaxel-estranustine exhibit a high percentage of decreased PSA response 
than patients with mitoxantrone, and an increased of life expectancy by 15% (Petrylak et 
al., 2004). However, treatment of docetaxel-estramustine shows greater toxicity and side-
effects. The potential of its therapeutic role in clinic needs well-designed trials before 
application. 
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1.2 Semaphorins and plexins 
1.2.1 Overview of semaphorins and plexins 
Semaphorins are a large family of secreted or membrane-bound proteins which 
were  discovered  as  axon  guidance  cues  in  developing  neuron  system.  In  the  neural 
system semaphorins regulate axon guidance, axonal fasciculation, dendritic guidance and 
neuronal migration (Kolodkin et al., 1993; Luo et al., 1993). It has subsequently been 
shown that semaphorins are involved in a wide range of biological processes including 
neural  development,  immune  responses,  morphogenesis,  angiogenesis  and  tumor 
progression (Conrotto et al., 2005; Giordano et al., 2002; Ishida et al., 2003; Kanda et al., 
2007). Plexin family members are single-pass transmembrane proteins and are the main 
receptors for semaphorins (Tamagnone et al., 1999). Both semaphorins and plexins are 
characterised  by  a  sema  domain,  a  ~500-amino  acid  conserved  region,  at  their  NH2-
terminal end. Up to date more than 30 semaphorins have been identified and classified 
into eight classes on the basis of sequence similarity and structural features (Semaphorin 
Nomenclature  Committee,  1999)  (Figure  1.4.A).  Classes  1  and  2  are  found  in 
invertebrates, classes 3 to 7 are present in vertebrates, and class V are virus encoding 
semaphorins. Among them, classes 2, 3 and V are secreted proteins. Classes 1, 4, 5 and 6 
are transmembrane molecules, and class 7 associates with the cell membrane through a 
glycosylphosphatidylinositol-anchor  motif  (Nakamura  et  al.,  2000).  Nine  mammalian 
plexins have been identified and classified into four subfamilies: plexin-A1 to plexin-A4, 
plexin-B1 to plexin-B3, plexin-C1, plexin-D1 (Tamagnone et al., 1999) (Figure 1.4.B). 
There are two plexins found in invertebrate species. 29 
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1.2.2 Structural organization of semaphorins and plexins 
  Semaphorins and plexins share an extracellular region of homology called the 
sema domain. This evolutionarily conserved domain is also found in the scatter factor 
receptors,  MET  and  RON.  The  sema  domain  features  a  seven-blade  β-propeller  fold 
which is structurally similar to the β-propeller repeats of α integrins (Antipenko et al., 
2003;  Love  et  al.,  2003).  The  sema  domain  is  crucial  for  mediating  protein-protein 
interaction  and  transducing  signals  in  both  semaphorins  and  plexins.  Immediately  C-
terminal to the sema domain, all semaphorins with exception of some viral semaphorins 
contain a cysteine-rich domain (CRD). This motif is also referred as plexin-semaphorin-
integrin (PSI) domain (Bork et al., 1999). At the sites C-terminal to PSI, semaphorins 
show great variation. Classes 2, 3, 4 and 7 semaphorins all contain a single copy of an 
immunoglobulin-like  domain  while  class  5  semaphorins  are  unique  in  having  seven 
thrombospondin repeats. 
In  contrast  to  semaphorins,  plexins  have  a  more  uniform  domain  structure. 
Plexins have three copies of PSI domain following the sema domain at the carboxyl-end 
(Gherardi et al., 2004).  Immediately C-terminal next to PSI domains, there are three IPT 
(Ig domain shared by plexins and transcription factors) (Bork et al., 1999). The plexin B 
family members are unique in having a convertase-cleavage site next to IPT domains 
(Artigiani et al., 2003). The cytoplasmic moiety of plexins (~600 amino acids) is highly 
conserved  among  all  family  members  and  is  crucial  for  initiating  intracellular  signal 
pathways (Tamagnone et al., 1999). The cytoplasmic portion of plexins contains two 
domains, C1 and C2, which are highly conserved in all plexins. These domains show 31 
 
sequence similarity to guanine triphosphatase activating protein (GAP) for small GTPase 
R-Ras  (Oinuma  et  al.,  2004a;  Rohm  et  al.,  2000).  C1  and  C2  contain  primary  and 
secondary Arg motifs which are the crucial structural features of various GAPs catalytic 
domains.  The  linker  region  between  C1  and  C2  is  more  divergent  among  plexin 
subfamilies. Within this linker region plexins bind to small GTPases such as Rnd1, Rac1 
and RhoD (Tong et al., 2007; Vikis et al., 2000). There is a CRIB-like (Cdc42/Rac-
interactive binding) motif in plexins A and B (Vastrik et al., 1999; Vikis et al., 2000). 
However, the CRIB-like motif is not involved in the interaction between these GTPases 
and plexin-B1 (Tong et al., 2007). Structural study shows that this region has a ubiquitin-
like fold that is also found in Ras-binding proteins (Tong and Buck, 2005). The extreme 
C-terminal of plexins B also have a PDZ-domain-binding motif through which plexins 
interact with GTPase-exchanger factors (GEFs) such as PDZ-Rho GEF and Rac GEF 
FARP2 (Driessens et al., 2002; Toyofuku et al., 2005). In association with monomeric G-
proteins  plexins  can  trigger  multiple  signalling  pathways  in  response  to  semaphorin 
stimulation. 
 
1.2.3 The interactions of semaphorins and plexins 
Semaphorins bind to their high-affinity receptors plexins to mediate cell migration, 
cytoskeletal  remodelling,  integrin-dependent  adhesion,  axon  guidance,  and  other 
biological processes. It is believed that semaphorin binding releases the autoinhibition of 
plexin and induces clustering of plexins, resulting in plexin activation (Takahashi and 
Strittmatter, 2001). Membrane-bound semaphorins bind directly to plexins through their 32 
 
sema domains. However, plexins alone are unable to interact with members of most class 
3 secreted semaphorins. An exception to this rule is Sema3E which binds to plexin-D1 
directly independent of neuropilins (Gu et al., 2005). Neuropilins are required to form a 
receptor complex with class A plexins to enable the binding to class 3 semaphorins and 
subsequent signal transduction (He and Tessier-Lavigne, 1997; Kolodkin et al., 1997). 
Neuropilins are transmembrane proteins of ~900 amino acids in length with very short 
cytoplasmic tails which do not show any intrinsic enzyme activity (Takagi et al., 1991). 
Neuropilins alone have low affinity to semaphorins and are incapable of transducing the 
signalling of class 3 semaphorins. Two neuropilins, neuropilin-1 and neuropilin-2, have 
been identified. Neuropilin-1 forms a complex with Plexin-A to form a co-receptor for 
Sema3A, mediating repulsion between neurons and axons (He and Tessier-Lavigne, 1997; 
Kolodkin et al., 1997). Neuropilin-2 has the same structure as neuropilin-1 with only a 
slight difference in protein sequence. Sema3F binds to neuropilin-2/Plexin-A complex 
with high affinity to induce hippocampal mossy fibers (Bagri et al., 2003; Chen et al., 
1997). In contrast, Sema3C has similar binding affinities toward both neuropilin-1 and 
neuropilin-2 (Chen et al., 1997). 
 
1.2.4 Signalling of semaphorins and plexins 
  Tyrosine phosphorylation is a pivotal mechanism in semaphorin signalling. Upon 
semaphorin  stimulation,  plexins  become  phosphorylated  in  their  cytoplasmic  domain. 
Plexins  A  and  B  have  been  extensively  studied  to  determine  the  role  of  tyrosine 
phosphorylation in their signalling pathways and to determine which kinases are involved. 33 
 
Intracellular tyrosine kinases Fes and Fyn associate with class A plexins in a ligand-
independent  manner  (Mitsui  et  al.,  2002;  Sasaki  et  al.,  2002).  Sema3A  enhances  the 
binding of plexin-A1 and Fes. Fes phosphorylates plexin-A1 and the complex of CRAM 
(CRMP-associated  molecule)  and  CRMP2  (collapsing  response  mediator  protein), 
resulting in cell collapse in COS-7 cells and growth cones in dorsal root ganglion (DRG) 
neuron(Mitsui et al., 2002). Plexin-A2 associates with the tyrosine kinase Fyn. Active 
Fyn promotes the binding of plexin-A2 and CDK5 (cyclin-dependent kinase-5) (Sasaki et 
al.,  2002).  In  response  to  Sema3A  stimulation,  CDK5  phosphorylation  cascade  is 
activated through the phosphorylation site of Fyn (Sasaki et al., 2002). The substrate of 
CDK5, Tau, is phosphorylated subsequently. Class B plexins associate with the receptor 
tyrosine kinases Met and ErbB2 (discussed in later sections). 
  In  addition  to  tyrosine  kinases,  Rho  GTPases  have  also  been  implicated  in 
semaphorin signalling. The Rho GTPases are a group of small G proteins that control cell 
motility through actin reorganization. In association with Rho GTPases, plexins mediate 
cell migration through regulation on actin rearrangement. As described in section 1.2.2, 
the binding site for Rac, Rnd1 and RhoD is located in the cytoplasmic domain of plexin-
A1.  Rac  functions  upstream  of  plexin-A1  and  Rac  activity  is  necessary  for 
Sema3A/plexin-A1-induced  cell  collapse  in  COS-7  cells  (Turner  et  al.,  2004).  Rnd1 
stimulates plexin-A1-induced cell collapse; however, RhoD exerts antagonistic effect of 
Rnd1 on plexin-A1 activation (Zanata et al., 2002). B-type plexins act as R-Ras and M-
Ras GAPs. The features of plexins B will be discussed in later sections. 
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1.2.5 Biological functions of semaphorins 
1.2.5.1 Semaphorins and neural development  
  During  development  of  neuron  network,  individual  axons  are  guided  to  their 
targets by sensing an array of environmental cues through the growth cones at the tip of 
axons (Song and Poo, 2001). Semaphorins are one of the categories of axon guidance 
cues,  acting  as  repellents  or  attractants  for  navigating  axons.  Grasshopper  Sema  I 
(fasciclin  I) is  the  first  identified semaphorin and is  expressed in the  circumferential 
stripes of epithelial cells in developing limb buds, where the growth cones of pioneer 
sensory  axons  make  a  characteristic  turn  while  extending  toward  the  central  nervous 
system (CNS) (Kolodkin et al., 1992). Blocking expression of Sema I in these stripes 
perturbs the trajectory of tibial pioneer growth cones. The Drosophila Sema1a shares 
homology in sequence to grasshopper Sema I and acts as an axonal repellent for motor 
axons, so that the motor neurons project to their target muscles precisely during embryo 
development (Yu et al., 1998). 
  Sema3A,  the  first  identified  vertebrate  semaphorin,  induces  retraction  and 
collapse  of  growth  cones  (Luo  et  al.,  1993).  Through  exerting  repulsive  effects  on 
developing  axons,  Sema3A  repels  axons  of  sympathetic,  motor  and  sensory  neurons 
away from the trigeminal, facial, vagal cranial ganglia, olfactory sensory, pontocerebellar 
mossy fiber and cortical neurons (Adams et al., 1997; Bagnard et al., 1998; Kobayashi et 
al., 1997; Rabacchi et al., 1999; Shepherd et al., 1996). Invertebrate axons are projected 
from neurons in the dorsal root ganglia (DRG) to different dorsoventral termini during 
the developmental process. At appropriate developmental stages high levels of Sema3A 35 
 
expression in the ventral spinal cord prevents non-mature sensory afferent neurons from 
entering the dorsal cord (Messersmith et al., 1995). In Semaphorin 3A mutant mice, some 
sensory axons project into inappropriate regions of the spinal cord. In addition, these 
mutant  mice  exhibit  an  abnormal  pattern  of  development  in  neuronal  processes, 
embryonic  bone  and  ventricle  structure  of  heart  (Behar  et  al.,  1996).  In  the  chicken 
embryo, Sema3A mediates the projection of olfactory sensory axons (Renzi et al., 2000). 
At the stage when axons first reach the telencephalon and undergo their waiting period 
before contacting olfactory bulb, Sema3A expression is strongest (embryonic day 5 to 7). 
The expression of Sema3A decreases at embryonic day 9 when axons invade into the 
bulb. The temporal pattern of Sema3A expression contributes to the precise control of 
axonal pathfinding. Multiple class 3 semaphorins are involved in fine-tuning the axonal 
growth  during  neuron  projection.  Their  regulatory  effects  on  axon  guidance  are 
bifunctional and dependent on the spatial expression pattern of semaphorins.  During 
cortical  development  Sema3E  is  able  to  attract  cortical  axons,  in  contrast  Sema3D 
inhibits axonal branching by inducing growth cone collapse (Bagnard et al., 1998). At the 
time  when  corticofugal  projections  are  established,  Sema3D  and  Sema3E  are  both 
expressed in the cortex. Sema3D is restricted in the ventricular zone of the neocortex 
whereas Sema3E is expressed in the subventricular zone. The synchronized expression of 
multiple semaphorins, both temporally and spatial, is responsible for the precise control 
of neural development. 
  The balance of attractive and repulsive semaphorins is responsible for mediating 
axonal fasciculation. Fasciculation is the process of segregating bundles of axons serving 
related functions at their appropriate targets. Peripheral axons of trigeminal, facial, vagal, 36 
 
accessory and glossopharyngeal nerves are driven together into fascicles by the Sema3A 
protein secreted by their surrounding tissues (Kitsukawa et al., 1997; Taniguchi et al., 
1997). Sema3A knockout mice demonstrate a highly defasciculated phenotype in these 
nerves. However, defasciculated axons are able to project near the surrounding area of 
their appropriate trajectories and targets, indicating that other molecules are involved in 
the process of axon guidance. 
 
1.2.5.2 Semaphorins and immune system 
  Several viral and vertebrate semaphorins have been implicated in various phases 
of the immune response. Sema4D (also known as CD100) is the first semaphorin that has 
been well characterized in the immune system. Sema4D is constitutively expressed on T 
cells and expression levels are relatively low on B cells. In the immune system Sema4D 
recognizes  CD72  rather  than  plexin-B1  as  its  receptor  (Kumanogoh  et  al.,  2000). 
Transfection of Sema4D into human B cells promotes their aggregation and survival in 
vitro  (Hall  et  al.,  1996).  Sema4D-deficient  mice  exhibit  severe  abnormal  B  cell 
development and altered immune response (Shi et al., 2000). Sema4D ligation with CD72 
turns off the inhibitory effect of CD72 on B cells, thus enhancing B cell activation. The 
interaction  of  Sema4D/CD72  also  enhances  CD40-dependent  B  cell  activation 
(Kumanogoh et al., 2000). Given the fact that Sema4D and CD72 are expressed in T cells 
and B cells respectively, it is conceivable that Sema4D/CD72 signalling is involved in T 
cell-B cell interaction. Extensive study also reveals that Sema4D is crucially involved in 
initiating activation and differentiation of T cells. In mice deficient of Sema4D, CD4
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cells  from  the draining  lymph  nodes  show impairment of proliferative  responses and 
cytokine  production  after  antigen  re-stimulation  (Shi  et  al.,  2000).  Soluble  human 
Sema4D  inhibits  the  spontaneous  and  MCP-3-induced  migration  of  freshly  isolated 
monocytes  and  monocytic  cell  lines,  suggesting  that  Sema4D  also  plays  a  role  in 
monocyte and macrophage migration (Delaire et al., 2001). 
  Sema4A is another member of class IV semaphorin subfamily and is implicated in 
regulation of T cell-mediated immune responses. Recombinant soluble Sema4A enhances 
T cell proliferation and IL-2 production after anti-CD3 antibody stimulation (Kumanogoh 
et al., 2002). Both in vitro and in vivo studies show that deficient expression of Sema4A 
results in impaired T cell priming (Kumanogoh et al., 2002; Kumanogoh et al., 2005). In 
addition,  soluble  Sema4A  enhances  the  interaction  between  allogeneic  T  cells  and 
dendritic cells (DCs) (Kumanogoh et al., 2002). Anti-Sema4A monoclonal antibodies 
block these mixed lymphocyte reactions, suggesting that Sema4A helps T cell activation 
through influencing the stimulatory interactions between T cells and DCs. 
  At the later stage of T cell-mediated immune response, inflammatory responses 
were  triggered  by  antigen-specific  effector  T-cells  through  macrophage  activation  in 
peripheral  tissues.  Sema7A  is  highly  involved  in  this  phase.  Sema7A  expressed  on 
activated T cells promotes macrophage recruitment to the site of inflammation. Through 
interaction with α1β1 integrins, Sema7A initiates inflammatory cascades by stimulating 
cytokine production by macrophages (Suzuki et al., 2007). 
  Semaphorin receptors, plexins, have also been implicated in immune response. 
Plexin-A1  is  expressed  in  DCs  and  is  involved  in  interaction  of  T  cells  and  DCs. 38 
 
Expression of plexin-A1 in DCs is required for production of antigen-specific T cells in 
the presence of cognate antigens. Plexin-A1 deficient DCs fail to activate T cells both in 
vitro and in vivo (Takegahara et al., 2006).  
 
1.2.5.3 Semaphorins and vascular morphogenesis 
Vasculature  is  composed  of  large  vessels  that  branch  into  small  vessels  and 
capillaries.  The  process  of  vasculature  formation  is  mediated  by  endothelial  cell 
movement. Semaphorins are highly involved in regulating guidance and remodelling of 
the vasculature. Sema6D and its  receptor plexin-A1 are  expressed in  endothelial and 
myocardial cell populations during the early stages of embryonic development in chicken 
and mouse (Toyofuku et al., 2004a; Toyofuku et al., 2004b). Sema6D plays dual roles in 
coordinating  the  narrowing  and  bending  of  the  developing  ventricular  chamber  by 
enhancing  and  inhibiting  cell  migration  of  conotruncal  segments  and  ventricle, 
respectively  (Toyofuku  et  al.,  2004a).  Plexin-A1  and  other  co-receptors  mediate  the 
bifunctions of Sema6D. In association with plexin-A1 and the coreceptor OTK (receptor 
tyrosine kinase Off-track), Sema6D exerts its repulsive effect on ventricular expansion. 
When Sema6D forms a complex with plexin-A1 and receptor tyrosine kinase VEGFR2, 
Sema6D is acting as attractant for conotruncal segment cell migration. In addition to its 
role  in  regulating  endothelial  cell  migration,  Sema6D  is  also  crucial  in  myocardial 
organization. Ab1 kinase is recruited to Sema6D and activated in the presence of plexin-
A1,  resulting  in  phosphorylation  of  Sema6D.  This  is  an  example  of  reverse  plexin 
signalling that is common in many other plexin members. The activation of Sema6D 39 
 
signalling  pathway  enhances  the  migration  of  myocardial  cells  into  the  trabeculae. 
Sema6D or plexin-A1 knockdown results in thin and small ventricular compact layer and 
defective trabeculation in chicken heart development (Toyofuku et al., 2004b). 
  Class  3  semaphorins  are  also  involved  in  the  development  of  cardiovascular 
system.  Mice  deficient  of  Sema3A  exhibit  cardiac  defects,  phenotyped  with  right 
ventricular hypertrophy and a grossly dilated right atrium (Behar et al., 1996). Sema 3C 
regulates crest cell migration into the proximal cardiac outflow tracts (Feiner et al., 2001). 
Sema3C  knockout  mice  display  strong  dysfunctions  of  vasculature,  characteristic  of 
disruption of the aortic arch and inappropriate separation of the cardiac outflow tracts 
(Feiner  et  al.,  2001).  These  severe  cardiovascular  system  defects  cause  death  within 
several hours after birth. In the mouse Sema3E secreted by developing somites controls 
the  patterning  of  the  growing  vasculature  through  repelling  plexin-D1-expressing 
endothelial cells growing. Deletion of Sema3E or plexin-D1 discrupts vascular patterning. 
These  facts  together  show  that  class  3  semaphorins  play  important  role  during  the 
development of cardiovascular system. 
 
1.2.5.4 Semaphorins and cancer 
Consistent  with  their  regulatory  role  in  fundamental  cell  behaviours  including 
migration,  semaphorins  are  also  involved  in  cancer  and  tumorigenesis.  Sema3B  and 
Sema3F  have  been  revealed  as  potential  tumor  suppressors,  as  they  are  located  in 
chromosome 3p21 where homozygous deletion is frequent in lung and ovarian cancers 40 
 
(Roche et al., 1996; Tse et al., 2002; Xiang et al., 1996). Hypermethylation of Sema3B 
promoter is observed in several human lung cancer cell lines and primary tumors (Kuroki 
et al., 2003). Both hypermethylation and loss of heterozogosity (LOH) are correlated with 
loss of expression of Sema3B mRNA. Sema3B inhibits lung cancer cell growth in tumor 
cells. In both lung and breast cancer, Sema3B induces apoptosis partly through blocking 
the VEGF autocrine activity (Castro-Rivera et al., 2004). Yet Sema3B can also be pro-
metastatic.  In  vivo  study  shows  that  Sema3B  inhibits  tumor  growth  but  induces 
metastasis (Rolny et al., 2008). Rolny et al. found that Sema3B induces the production of 
interleukin  (IL) 8 by tumor cells  through activating the p38-mitogenactivated protein 
kinase  pathway.  The  released  IL-8  then  induces  the  recruitment  of  tumor-associated 
macrophages and metastatic dissemination to the lung. Sema3F expression is found to be 
down-regulated in lung tumors and cell lines (Lantuejoul et al., 2003). Transfection of 
Sema3F in A9 fibrosarcoma cells abolishes tumorigenecity in nude mice, suggesting its 
tumor suppressor role (Tse et al., 2002). In addition, Sema3F has inhibitory effects on 
cell attachment and spreading in breast cancer cell line MCF7, opposite to the effect of 
VEGF (Nasarre et al., 2003). Furthermore, Sema3F also acts as an inhibitor of tumor 
angiogenesis. Over-expression of Sema3F in tumorigenic cell line HEK293 inhibits its 
tumor-formation  ability  and  suppresses  tumor-associated  blood  vessels  concentration 
(Kessler  et  al.,  2004).  In  mice  implanted  with  Sema3F-expressing  metastatic  human 
melanoma cells, tumor displays less invasive and vascular phenotype (Bielenberg et al., 
2004). Other members in class 3 semaphorins, such as Sema3A, Sema3D, Sema3E and 
Sema3G  have  also  been  characterised  as  tumor  suppressors  and  inhibitors  of  tumor 
angiogenesis (Kigel et al., 2008). All these four semaphorins possess anti-tumorigenic 41 
 
properties. In addition Sema3A, Sema3D and Sema3G strongly reduce the density of 
blood vessels in tumors. 
Besides  their  suppressive  role  in  tumor  development,  semaphorins  can  also 
function as tumor promoters. Over-expression of Sema3E and Sema3C are both found to 
be correlated to the invasive and metastatic behaviours or drug resistance of tumor cells 
(Christensen et al., 1998; Martin-Satue and Blanco, 1999; Yamada et al., 1997). The 
report on Sema3E as a promoter of cancer is in contrast to the finding by Neufeld’s group 
that Sema3E acts as a tumor suppressor. This might be explained by the difference of 
tumor types and whether the appropriate semaphorin receptors are expressed. Sema4D 
induces invasive growth and angiogenesis of endothelial cells through recruitment of Met 
to plexin-B1 (Conrotto et al., 2005; Giordano et al., 2002). Over-expression of Sema4D 
occurs in several carcinomas including breast, colon, lung and prostate cancers (Basile et 
al., 2006; Wong et al., 2007). Yet Sema4D also acts as a tumor suppressor in melanoma. 
The  Sema4D  receptor  plexin-B1  blocks  tumorigenesis  in  primary  melanoma  and 
suppresses migration in late-stage cells (Argast et  al.,  2009). The opposite effects  of 
Sema4D on tumor may be due to  co-receptors or binding partners of  plexin-B1 that 
activates  different  signalling  pathways.  Signaling  pathways  transduced  by 
Sema4D/plexin-B1 will be discussed in section 1.3. 
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1.3 Signalling pathways of Sema4D/plexin-B1 
  Plexin-B1 is the receptor for Sema4D. Like the other members of plexin family, 
plexin-B1 has the Sema domain at  the extracellular region,  through which plexin-B1 
interacts with its ligand Sema4D and with tyrosine kinases. The cytoplasmic domain of 
plexin-B1  is  characteristic  of  the  general  features  of  B  plexins,  with  two  segments 
homologous to R-Ras GAP linked by a region where several small Rho GTPases bind. 
Sema4D is the ligand for plexin-B1. The signalling pathways of Sema4D/plexin-B1 have 
been  extensively studied recently. Since  plexin-B1 lacks  an intrinsic tyrosine kinases 
activity,  plexin-B1  interacts  with  other  partners  to  initiate  signalling  pathways.  For 
example,  small  GTPases  are  importantly  involved  in  Sema4D/plexin-B1  signal 
transduction. Tong and his colleagues have defined the small Rho GTPase binding site in 
the  linker  region  of  the  two  homologous  segments  (C1  and  C2)  in  the  cytoplasmic 
domain of plexin-B1. An ubiquitin-like fold consisting of β-strands 3 and 4 and a short α-
helical segment located in the cytoplasmic domain of plexin-B1 is the site for interaction 
with Rac1, Rnd1 and RhoD (Tong et al., 2007). This binding motif is adjacent to the 
region where plexin-B1 protein is dimerized. Binding of these three GTPases induces a 
conformational  change  that  destabilizes  the  dimer;  this  is  necessary  for  activation  of 
plexin-B1 signalling pathways involving Rho GTPases (Oinuma et al., 2004b; Oinuma et 
al., 2004a; Tong et al., 2007). Plexin-B1 also couples to receptor tyrosine kinases such as 
ErbB-2  and Met to  initiate signalling pathways. Figure 1.5 illustrates the network of 
plexin-B1 signalling pathways. By binding to ErbB-2 or to Met, plexin-B1 mediates cell 
motility through regulating Rho activity in response to Sema4D. Small GTPases, Rac, 
Rnd  and  RhoD,  bind  to  plexin-B1  at  the  same  site.  Active  Rac  is  sequestered  from 43 
 
interacting  with  PAK  by  plexin-B1.  Rnd1  constitutively  binds  to  plexin-B1.  Upon 
Sema4D stimulation, plexin-B1/Rnd1 hydrolyses  R-Ras  GTP  through its  R-Ras  GAP 
activity.  In  the  following  sections  I  will  review  these  proteins  involved  in 
Sema4D/plexin-B1  signalling  and  the  cell  functions  regulated  by  these  signalling 
pathways. 44 
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Figure 1.5 Sema4D/plexin-B1 transduction pathways. Sema4D/plexin-B1 transduces its
signal through coupling with other proteins and forms a complex signaling network. Plexin-
B1 binds to Rnd1, Rac, PDZ-RhoGEF and R-Ras. Upon Sema4D stimulation, the R-Ras
GAP activity of plexin-B1 is activated, resulting in hydrolysis of R-Ras GTP. Plexin-B1 is
thought to sequester Rac GTP from downstream effectors such as PAK. Tyrosine kinases
ErbB-2 and Met (not shown in this figure) bind to plexin-B1 through the extracellular
domains. Sema4D stimulation activates ErbB-2 which subsequently phosphorylates plexin-
B1 on tyrosines 1708 and 1732. The phosphorylated plexin-B1 recruits PLCγ which activates
PDZ-RhoGEF, resulting in Rho activation.
Key
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1.3.1 Rac1 
   Firstly, role of Rac1 and plexin-B1 interaction for plexin-B1 signal transduction 
will be discussed in this section. 
  Rac, Rho and Cdc42 comprise the Rho GTPase family proteins that are the key 
factors controlling cell motility through regulating the actin cytoskeleton and microtubule 
dynamics. Rho regulates stress fiber formation, whereas activation of Rac and Cdc42 
controls formation of lamellipodia and filopodia, respectively. Neither Rho nor Cdc42 
binds  to  plexin-B1.  Rac1  in  its  active  form,  Rac1-GTP,  interacts  directly  with 
cytoplasmic domain of plexin-B1 (Driessens et al., 2001; Vikis et al., 2000). The effector 
domain of Rac1 is required for its interaction with plexin-B1. Mutations at residues Y32, 
T34 and F37 completely abolish the ability of Rac to bind to plexin-B1 (Vikis et al., 
2000). The ligand for plexin-B1, Sema4D, enhances the interaction between plexin-B1 
and Rac. 
PAK (p21-activated kinase) is a Rac downstream effector that is activated when 
Rac1  binds  to  its  Rac-binding  domain  (RBD).  Plexin-B1  and  PAK  compete  for  Rac 
binding. By sequestering active Rac from interacting with PAK, plexin-B1 inhibits Rac-
induced PAK  activation  (Vikis  et  al.,  2002). On the other side, Rac  interaction with 
plexin-B1 enhances plexin-B1 expression at the cell membrane and slightly increases its 
receptor  affinity,  resulting  in  elevated  interaction  between  plexin-B1  and  its  ligand 
Sema4D  (Vikis  et  al.,  2002).  However,  in  cells  co-expressing  plexin-B1  and  PDZ-
RhoGEF Rac has no effect on surface expression of plexin-B1 (Swiercz et al., 2004). In 
these cells active Rac increases Sema4D-induced tyrosine phosphorylation of plexin-B1. 46 
 
These observations suggest that active Rac promotes plexin-B1 phosphorylation either by 
increasing  the  affinity  for  Sema4D  or  by  other  mechanism  that  facilitates  Sema4D-
induced phosphorylation. 
  Given  that  semaphorins  forms  dimers  and  activate  plexins  through  clustering, 
Sema4D activates plexin-B1 through clustering (Klostermann et al., 1998; Tamagnone et 
al., 1999). Driessens et al. constructed a chimeric protein in which cytoplasmic plexin-B1 
is  fused  to  the  transmembrane  and  extracellular  domains  of  CD2.  They  induced 
CD2/plexin-B1 clustering at  cell surface in fibroblasts and found that crosslinking of 
plexin-B1 results in formation of stress fibers and some cell contraction, a phenotype 
characteristic of Rho activation (Driessens et al., 2001). No lamellipodial actin is detected 
suggesting Rac is not activated by crosslinking of plexin-B1. Dominant-negative Rac 
(N17)  completely  blocks  the  formation  of  actin  stress  fibers  and  cell  contraction  in 
fibroblasts,  suggesting  that  RhoA  is  downstream  of  the  Rac1  response  to  plexin-B1 
activation through clustering. However, binding of Rac to plexin-B1 is not necessary for 
Rho activation, since cells expressing plexin-B1 lacking a Rac binding site still exhibit a 
Rho activation phenotype after plexin-B1 crosslinking. Another research group led by 
Oinuma shows that dominant negative Rac does not have an effect on cell contraction 
induced by Sema4D-mediated Rho activation in COS7 cells (Oinuma et al., 2003). These 
controversial findings of Rac1 on Sema4D/plexin-B1-mediated RhoA activation might be 
cell type-dependent. The crosstalk between Rac and Rho activation through plexin-B1 
clustering is not clear, and remains to be addressed by further studies. 
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1.3.2 Rnd1 
  Rnd GTPases, including Rnd1, Rnd2, and Rnd3, comprise a subfamily of Rho 
family GTPases. Rnd1 is characterised by a low affinity for GDP and  very low intrinsic 
GTPase  activities,  leading  to  its  constitutively  GTP-bound  state  (Foster  et  al.,  1996; 
Nobes et al., 1998). Rnd1 is abundantly expressed in the nervous system and has been 
implicated in regulation of cell cytoskeleton and cell adhesion. Expression of Rnd1 in 
fibroblasts  results  in  cell  retraction  and  rounding,  loss  of  stress  fibers,  and  loss  of 
integrin-based focal adhesion (Nobes et al., 1998). Recently, Rnd1 has been found to be 
involved  in  semaphorin  signalling  pathways.  Before  Tong  revealed  the  structure  for 
GTPase  (Rac1,  Rnd1,  and  RhoD)  binding  in  the  cytoplasmic  domain  of  plexin-B1, 
Oinuma has shown that all Rnd subfamily GTPases interact with the cytoplasmic domain 
of plexin-B1 by immunoprecipitation (Oinuma et al., 2003; Tong et al., 2007). She has 
also narrowed down the binding site for Rnd1 between amino acids 1724 and 1915 of 
plexin-B1,  overlapping  with  Rac  binding  site  (aa1848-1890).  Rnd1  constitutively 
interacts with plexin-B1 independent of Sema4D. Interaction of Rnd1 and plexin-B1 is 
required  for  Sema4D-induced  cell  contraction  in  COS7  cells,  and  the  contraction  is 
through activation of PDZ-RhoGEF/RhoA pathway. Either inhibition of plexin-B1/PDZ-
RhoGEF interaction or suppression of RhoA by treatment with Rho-kinase inhibitor Y-
27632  abolishes  the  Sema4D-induced  cell  rounding  in  COS7  cells.  Rnd1  binding  to 
plexin-B1 enhances the interaction between plexin-B1 and PDZ-RhoGEF and potentiates 
Sema4D/plexin-B1-mediated Rho activation in COS7 cells. The mechanism of how Rnd1 
promotes  the  binding  between  plexin-B1  and  PDZ-RhoGEF  is  not  clear.  It  is 
hypothesized that interaction of Rnd1 and plexin-B1 may elicit a conformational change 48 
 
in  the  cytoplasmic  domain  of  plexin-B1,  which  facilitates  the  interaction  of  PDZ-
RhoGEF  and  plexin-B1.  Swiercz  et  al.  also  reported  that  Rnd1  increases  surface 
expression of plexin-B1 in cells co-expressing plexin-B1 and PDZ-RhoGEF, which is 
consistent with the finding that Rnd1 promotes the interaction between plexin-B1 and 
PDZ-RhoGEF (Swiercz et al., 2004). This enhanced localization of plexin-B1 by Rnd 
may  also  explain  the  observation  that  Rnd1  increases  Sema4D-induced  tyrosine 
phosphorylation of plexin-B1 in cells co-expressing plexin-B1 and PDZ-RhoGEF. 
Recently, plexin-B1 has been reported functioning as a GAP for R-Ras. Rnd1 is 
also critically involved in stimulating the R-Ras GAP activity of plexin-B1. The R-Ras 
GAP homology domains in cytoplasmic region of plexin-B1, C1 and C2, bind to each 
other in natural state (Oinuma et al., 2004b). Rnd1 binding to the linker region located 
between C1 and C2 disrupts this interaction. This Rnd1-induced conformation change is 
indispensable for R-Ras binding and Sema4D-mediated GAP activity toward R-Ras of 
plexin-B1.  Detailed  discussion  regarding  the  GAP  activity  of  plexin-B1  will  be 
introduced in section 1.3.3. Rnd1 association with plexin-B1 is also required for initiation 
of Sema4D/plexin-B1-mediated M-Ras GAP activity that will be introduced in section 
1.3.4. 
 
1.3.3 R-Ras 
  R-Ras belongs to the Ras family which comprises a large group of small GTPases 
with similar structures and related functions (Kinbara et al., 2003). Like most of the small 49 
 
GTPases, R-Ras cycles between an inactive GDP (guanine diphosphate)-bound state and 
an  active  GTP-bound  state.  The  active  form  of  R-Ras  increases  cell  adhesion,  cell 
migration, and neurite outgrowth by activating integrins (Keely et al., 1999; Zhang et al., 
1996). The activation of R-Ras is down-regulated by GTPase-activating proteins (GAP) 
that stimulate the intrinsic GTPase activity of R-Ras, resulting in the hydrolysis of GTP-
bound R-Ras into GDP-bound state. In addition to p98-R-RasGAP, activated plexin-B1 
also acts as an R-Ras-specific GAP (Oinuma et al., 2004b; Oinuma et al., 2004a). Rnd1 
binding to plexin-B1 opens the closed conformation of the cytoplasmic domain of plexin-
B1, making plexin-B1 accessible for GTP-bound R-Ras binding. Activation of plexin-B1 
by Sema4D results in clustering of plexin-B1, which stimulates the R-Ras GAP activity 
of Rnd1-associated plexin-B1. Therefore R-Ras activity is decreased through hydrolysis 
of GTP by R-Ras GAP activity and this phenomenon follows the same time course as 
plexin-B1 clustering. Clustering of Rnd-1-bound cytoplasmic domain of plexin-B1 by an 
antibody also initiates the R-Ras GAP activation, indicating that receptor clustering is a 
requisite step for expression of R-Ras GAP activity of plexin-B1. The Sema4D/plexin-B1 
stimulated R-Ras GAP activity is responsible for cell collapse in COS7 cells, growth 
cone collapse and reduced neurite growth in rat hippocampal neurons (Oinuma et al., 
2004b; Oinuma et al., 2004a). Thus plexin-B1 regulates Sema4D-induced repulsive axon 
guidance signalling through its R-Ras GAP activity. 
Although Rnd1 is necessary for both PDZ-RhoGEF-mediated RhoA activation 
and  R-Ras  GAP  activity  of  Sema4D/plexin-B1  signalling  pathways,  the  plexin-B1-
induced  suppression  of  R-Ras  activity  is  independent  of  plexin-B1-mediated  RhoA 
activation. Inhibition of either activity does not affect the other. However inactivation of 50 
 
either pathway results in inhibition of neurite retraction (Oinuma et al., 2004a; Perrot et 
al.,  2002;  Swiercz  et  al.,  2002).  Thus  both  R-Ras  GAP  activity  and  PDZ-RhoGEF 
mediated RhoA activation are required for Sema4D/plexin-B1-induced neurite retraction. 
PI3K, an upstream kinase of Akt and GSK-3β has been reported to be involved 
downstream  of  plexin-B1-mediated  R-Ras  GAP  activity.  Activated  GSK-3β 
phosphorylates CRMP2 (collapsing response mediator protein 2) to suppress its ability to 
promote microtubule polymerization and stabilization,  leading  to  inhibition  of axonal 
elongation. Phosphorylated PI3K is a negative regulator on GSK-3β activity. Sema4D 
induces a decrease in Akt phosphorylation and GSK-3β, resulting in activation of GSK-
3β and subsequent phosphorylation of CRMP2 in hippocampal neurons (Ito et al., 2006). 
This alteration follows the same time course as Sema4D-induced cell rounding in COS7 
cells.  Plexin-B1  lacking  R-Ras  GAP  activity  does  not  initiate  Akt/GSK-3β/CRMP2 
phosphorylation  in  response  to  Sema4D,  indicating  that  the  R-Ras  GAP  activity  is 
required for Sema4D/plexin-B1-induced inactivation of PI3K/Akt and activation of GSK-
3β. Thus plexin-B1 induces growth cone collapse by activating GSK-3β through its R-
Ras GAP activity in response to Sema4D. 
  Integrins are a family of cell surface receptors that bind to the ECM. Activation of 
integrins is essential for cell adhesion and migration (Hood and Cheresh, 2002). Integrins 
are  regulated  by  activated  R-Ras  that  induces  integrin  activation  and  increase  cell 
adhesion and matrix assembly (Sethi et al., 1999; Zhang et al., 1996). Suppression of R-
Ras results in decreased cell adhesion and neurite growth. Barberis and his colleagues 
have reported that Sema4D/plexin-B1 signalling inhibits integrin-mediated cell adhesion 51 
 
and migration independent of Rho-kinase activity in a variety of cell lines (Barberis et al., 
2004). The R-Ras GAP activity of plexin-B1 is found to be responsible for the inhibition 
of  integrin-based  adhesion  and  migration.  Through  its  R-Ras  GAP  activity,  activated 
plexin-B1 suppresses the ECM-dependent R-Ras activation and downstream PI3K kinase 
activity, subsequently resulting in inhibition of cell migration through inactivation of β1 
integrin (Oinuma et al., 2006). 
 
1.3.4 M-Ras 
  M-Ras belongs to the Ras GTPase family and shares relatively similar homology 
with  R-Ras.  Distinct  from  the  regulatory  role  of  R-Ras  in  axonal  growth,  M-Ras  is 
involved in the process of dendritic outgrowth and branching. M-Ras is predominantly 
expressed in the central nervous system of both human and mouse and it is particularly  
abundant in the cortex and hippocampus revealed by in situ hybridization (Kimmelman et 
al., 2002). In primary cultured cortical neurons from E18.5 rats, expression of M-Ras 
increases during the stage when dendrites begin to grow and it is required for normal 
dendrite development in cortical neurons (Saito et al., 2009). M-Ras knockdown impairs 
dendritic outgrowth and branching, while over-expression of constitutively active M-Ras 
promotes dendrite growth. In differentiated PC12 cells M-Ras stimulates the extracellular 
signal-regulated  kinase  (ERK)  pathway  through  activating  B-Raf,  thereby  promoting 
neurite outgrowth (Kimmelman et al., 2002; Sun et al., 2006). Plexin-B1 is associated 
with  active  M-Ras  and  the  interaction  between  plexin-B1  and  M-Ras  requires  Rnd1 
binding to plexin-B1 (Saito et al., 2009). Upon stimulation by Sema4D, M-Ras activity is 52 
 
suppressed  by  plexin-B1-mediated  M-Ras  GAP  activity.  The  down-regulated  M-Ras 
activity is correlated with Sema4D-induced dendrite remodelling in both cortical neurons 
and hippocampal neurons, indicating that Sema4D/plexin-B1 regulates remodelling of 
dendrite  morphology  through  its  GAP  activity  toward  M-Ras.  ERK  signalling 
downstream  of  M-Ras  is  responsible  for  the  Sema4D-induced  decrease  of  dendrite 
growth. Sema4D decreases ERK phosphorylation and over-expression of constitutively 
active form of upstream kinase of ERK, MEK1, blocks the Sema4D-reduced dendritic 
outgrowth  and  branching  (Saito  et  al.,  2009).  Therefore  Sema4D/plexin-B1  regulates 
axonal growth and dendrite morphology through its R-Ras GAP and M-Ras GAP activity, 
respectively. This dual role of Sema4D/plexin-B1 signalling pathway is crucial for its 
fine-tuning in the complex formation of the neuronal network. 
 
1.3.5 RhoD 
  RhoD GTPase is one of the members of the small GTPases and its functional 
properties in endosome dynamics have been well characterized. Protein RhoD localizes 
to the plasma membrane and early endosomes (Murphy et al., 2001). Over-expression of 
RhoD induces disassembly of stress fibres and focal adhesions, inhibits endosome fusion 
and decreases endosome motility (Murphy et al., 1996; Murphy et al., 2001). Therefore 
RhoD functions differently from other Rho family GTPase proteins and it functions to 
slow vesicle transport. Expression of constitutively active RhoD in the endothelial cells, 
BBCE, decreases cell motility. The role of RhoD in plexin signalling was firstly reported 
by Zanata’s group. They have shown that RhoD binds to plexin-A1 in a GTP dependent 53 
 
manner (Zanata et al., 2002). RhoD negatively regulates plexin-A1 signalling through 
inhibiting Rnd1-dependent cell collapse induced by Sema3A. Tong and his colleagues 
reported that plexin-B1 binds to RhoD through protein structure studies (Tong et al., 
2007). Yet there is no in vivo evidence of interaction between plexin-B1 and RhoD. The 
biological function regulated by plexin-B1/RhoD signalling remains to be elucidated. 
 
1.3.6 PDZ-RhoGEF/LARGE 
  PSD-95/Dlg/ZO-1  (PDZ)-RhoGEF  (GEF,  guanine  nucleotide  exchange  factor) 
and  leukemia-associated  RhoGEF  (LARG)  are  two  Rho-specific  guanine  nucleotide 
exchange factors that stimulate the GDP-GTP exchange reaction of RhoA (Fukuhara et 
al.,  1999;  Fukuhara  et  al.,  2000).  PDZ-RhoGEF  and  LARG  share  high  homology  in 
sequence and both proteins contain multiple domains, including a RGS (regulator of G 
protein signalling) domain, a DH (Dbl homology) domain, a PH (pleckstrin-homology) 
domain and a PDZ domain. PDZ-RhoGEF/LARG interact through their RGS domains 
with activated G12/G13, which couples GPCRs (G protein-coupled receptors) to RhoA and 
regulates RhoA activation (Fukuhara et al., 1999; Fukuhara et al., 2001). Activation of 
RhoA results in actin/myosin contractility and subsequent process retraction or growth 
cone collapse. The DH and PH domains of PDZ-RhoGEF/LARG are critical for their 
ability to stimulate nucleotide exchange towards GTPase for RhoA. The PDZ domain of 
PDZ-RhoGEF/LARG binds to a consensus motif (S/TXV) in the carboxyl termini of 
partner proteins or other PDZ domains. The extreme C-terminal of plexin-B1 contains a 
sequence of VTDL that conforms to a typical PDZ-binding motif (Aurandt et al., 2002). 54 
 
Several lines of evidence have shown that both PDZ-RhoGEF and LARG can specifically 
interact via their PDZ domains with the cytoplasmic PDZ-binding domain of plexin-B1 
to regulate RhoA and cell cytoskeleton organization (Aurandt et al., 2002; Swiercz et al., 
2002). Therefore PDZ-RhoGEF and  LARG  act  as  crucial signal transducers between 
plexin-B1 signalling and RhoA activation. 
  PDZ-RhoGEF/LARG and plexin-B1 in the nervous system show an overlapping 
expression pattern, providing supportive evidence for the interaction between plexin-B1 
and  PDZ-RhoGEF  in  neuronal  compartments  in  vivo  (Swiercz  et  al.,  2002).  PDZ-
RhoGEF and plexin-B1 both distribute over neuropil of the hippocampus in adult mouse 
brain. In dissociated chick retinal ganglion neurons in culture, both PDZ-RhoGEF and 
plexin-B1 are enriched in axonal growth cones and exhibit a large overlap with each 
other. Both immunoprecipitation and yeast two-hybrid analysis reveal that PDZ-RhoGEF 
interacts with plexin-B1 (Swiercz et al., 2002). Either deletion of C-terminal amino acids 
in plexin-B1 or mutants of PDZ-RhoGEF lacking the PDZ domain results in abrogation 
of this interaction, indicating this interaction is mediated by the PDZ domain of PDZ-
RhoGEF and the PDZ-binding motif in plexin-B1. In addition, PDZ-RhoGEF facilitates 
the enrichment of plexin-B1 at the plasma membrane. The PDZ domain is required for its 
binding to plexin-B1, whereas DH and PH domains are necessary for Sema4D/plexin-B1-
induced  Rho  activation  (Swiercz  et  al.,  2002).  Activation  of  plexin-B1  by  Sema4D 
activates  the  activity  of  DH  and  PH  domains  of  PDZ-RhoGEF,  resulting  in  RhoA 
activation  and  subsequent  growth  cone  collapse  in  primary  hippocampal  neurons, 
neurites retraction and cell rounding in differentiated rat pheochromocytoma (PC12) cells, 55 
 
and cell contraction in COS-7 cells (Oinuma et al., 2003; Perrot et al., 2002; Swiercz et 
al., 2002). 
LARG was identified as a mixed lineage leukemia fusion protein in patients with 
primary acute myeloid leukemia (Kourlas et al., 2000). The mechanism of LARG/plexin-
B1  interaction  is  the  same  as  that  for  PDZ-RhoGEF/plexin-B1.  The  PDZ  domain  of 
LARG contains a conserved structure which coordinates the protein’s interaction with its 
corresponding binding proteins. Mutation of lysine 77 within this structure significantly 
weakens the binding of LARG to plexin-B1, indicating that PDZ domain is crucial in 
mediating the LARG/plexin-B1 interaction. In addition, the interaction between plexin-
B1 and LARG is not dependent on Sema4D stimulation. LARG GEF activity is specific 
for the small GTPase RhoA (Reuther et al., 2001). Activation of plexin-B1 by Sema4D 
regulates coupled LARG, resulting in RhoA activation and further regulation of the cell 
cytoskeleton (Aurandt et al., 2002). 
The  PDZ-RhoGEF/LARG-mediated  RhoA  activation  is  an  important  step  for 
migratory and pro-angiogenic response elicited by Sema4D in endothelial cells (Basile et 
al., 2004; Basile et al., 2007). In response to Sema4D, plexin-B1 activates PI3K/Akt and 
MAPK pathways through RhoA by regulating the integrin-dependent signalling network 
(Aurandt et al., 2006; Basile et al., 2007). This point will be fully discussed in section 
1.3.10. 
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1.3.7 p190-RhoGAP 
  p190,  also  known  as  p190A,  is  a  ubiquitously  expressed  GTPase  activating 
protein (GAP). It is one of the main effectors of localized Rho down-regulation under the 
control of plasma membrane receptors and tyrosine kinases (Brouns et al., 2000). It has 
been shown that p190 plays a crucial role in regulating cytoskeletal dynamics through 
inhibiting focal adhesions and myosin-mediated F-actin contraction. Recently, it has been 
reported  that  p190  associates  with  plexins  and  is  required  for  semaphorin  signalling 
(Barberis  et  al.,  2005).  Plexin-B1  specifically  associates  with  p190-RhoGAP  and  the 
interaction transiently increases upon stimulation with Sema4D. p190-RhoGAP down-
regulates the RhoA activity and is required for semaphorin signalling functions in several 
different cell lines. Gene-deficient fibroblasts derived from p190
-/- mice do not exhibit 
disassembly  of  integrin-based  focal  adhesion  or  inhibition  of  cell-spreading  on 
fibronectin upon plexin-B1 activation. Re-introduction of p190 expression in this p190-
deficient  fibroblast  restores  the  phenotypes  of  disassembly  of  integrin-based  focal 
adhesion and subsequent collapse. Barberis et al. also found that HUVEC cells defective 
in p190 expression by siRNA do not demonstrate the retraction in response to Sema4D 
compared with the wildtype. All together, their findings reveal the mechanism of RhoA 
inactivation in Sema4D/plexin-B1 signalling. 
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1.3.8 Met and Ron 
  The  scatter  factor  receptors,  Met,  the  tyrosine  kinase  receptor  for  hepatocyte 
growth  factor  (HGF),  and  RON,  the  receptor  for  the  macrophage  stimulating  protein 
(MSP), are single-pass disulfide-linked α/β heterodimers with intrinsic tyrosine kinase 
activity (Gaudino et al., 1994; Naldini et al., 1991; Trusolino and Comoglio, 2002). In 
both  proteins,  the  α-chains  are  completely  extracellular,  whereas  the  β-chains  are 
transmembrane  subunits  containing  the  tyrosine  kinase  catalytic  sites.  Semaphorins, 
plexins, and scatter factor receptors are grouped into the semaphorin superfamily based 
on the structural homology of the extracellular sema domain. C-terminal next to the sema 
domain, both Met and RON have a copy of CRD that is termed as MRS (Met-related 
sequence), and four copies of an Ig domain, referred to as the transcription factor Ig 
domain (Gherardi et al., 2004). The cytoplasmic moieties of Met and RON are more 
divergent than their extracellular domain and are responsible for their kinase activity. 
Unlike wide expression of semaphorins and plexins across invertebrates and vertebrates, 
Met and RON proteins are only expressed in vertebrates. On ligand binding, Met and Ron 
become activated and trigger pleiotropic responses leading to invasive growth that is a 
complex  biological  programme  instructing  cell  dissociation,  migration,  colonization, 
proliferation,  and  differentiation.  Met  activation  is  implicated  in  many  biological 
processes such as epithelial morphogenesis, endothelial cell migration, and organization 
of new blood vessels during angiogenesis  (Grant et al., 1993; Weidner et al., 1993). 
  Both  Met  and  Ron  interact  with  all  the  three  members  of  plexin-B  family 
irrespective  of  ligand  binding  (Conrotto  et  al.,  2004).  This  interaction  requires  the 58 
 
extracellular domains of both receptors and is specific to all the class B plexins (Giordano 
et al., 2002). Sema4D stimulation induces phosphorylation of plexin-B1 and indirectly 
activates  Met  and  the  substrate  Gab-1  via  plexin-B1.  The  mechanism  underlying 
Sema4D-induced Met phosphorylation is not clear yet. However, it is hypothesized that 
Sema4D-induced plexin-B1 clustering drives oligomerization and activation of Met. Yet 
this needs to be further investigated and more evidence obtained. On Sema4D stimulation, 
Met and Ron are activated and promote invasive growth in several cell lines such as 
MLP29 and NIH 3T3. Suppression of Met activity results in impairment of Sema4D-
induced invasive growth of cells, indicating that recruitment of Met through plexin-B1 is 
crucial for Sema4D-induced invasive growth. Interestingly over-expression of plexin-B1 
is observed in several cancer cell lines derived from colon, liver, pancreas and gastric 
carcinomas, and the over-expressed plexin-B1 is constitutively tyrosine phosphorylated 
and associated with activated Met (Conrotto et al., 2004). Cells over-expressing plexin-
B1 exhibit constitutive invasive phenotypes including spontaneously formed branched 
structures, constitutive motility and anchorage-independent growth (Conrotto et al., 2004; 
Giordano et al., 2002). On the other side, over-expression of Met is frequent in human 
tumors  and  Ron  plays  oncogenic  role  in  several  human  carcinomas  (Danilkovitch-
Miagkova and  Zbar, 2002;  Maggiora  et  al.,  1998;  Zhou et  al.,  2003).  The cross-talk 
between  plexin-B1  and  scatter  factors  in  regulating  cell  invasion  provides  a  new 
mechanism of finely tuning the invasive growth program both in physiological conditions 
and in tumor growth and metastasis. 
  In addition to its regulatory role in invasive growth of cells, the Sema4D/plexin-
B1-induced Met activation is also involved in angiogenesis. In primary endothelial cells, 59 
 
Sema4D  stimulates  EC  migration,  capillary-like  tubes  formation,  and  cytoskeletal 
reorganization through activating Met coupled by plexin-B1. During brain development, 
Sema4D-induced  activation  of  plexin-B1-Met  complex  is  also  required  for  guiding 
GnRH-1 (Giacobini et al., 2008) cells to their appropriate destinations. Taken together 
scatter  factors  in  conjunction  with  plexin-B1  play  a  broad  spectrum  of  biological 
functions in migration, angiogenesis and embryonic development. 
 
1.3.9 ErbB-2 
  ErbB-2 (also known as HER2) is a member of the ErbB (epidermal growth factor 
receptor)  family  that  consists  of  four  closely  related  type  1  transmembrane  tyrosine 
kinase receptors, ErbB-1, ErbB-2, ErbB-3, and ErbB-4. They are potent mediators of 
normal cell growth and development and malfunctions of ErbB signalling network are 
correlated with cancer (Hynes and Lane, 2005; Yarden and Sliwkowski, 2001). ErbB-2 
has the common structure shared by all the family members, an extracellular domain, an 
α-helical transmembrane segment and an intracellular tyrosine kinase domain (Olayioye 
et al., 2000). However, ErbB-2 is unique as it does not have a known ligand and can only 
be activated by dimerization with one of the other three ErbB proteins. In the normal state, 
ErbB-2  exists  as  inactive  monomer  folded  to  prevent  dimerization.  ErbB-2  has  been 
strongly implicated in the development and progression of cancer. Over-expression of 
ErbB-2 has been reported in a number of human tumors including breast cancer, ovarian 
cancer, gastric carcinoma and salivary gland tumors (Jaehne et al., 1992; Slamon et al., 
1987; Vermeij et al., 2008). 60 
 
  ErbB-2 associates with all the three plexins of class B through the extracellular 
domains  of  both  receptors  (Swiercz  et  al.,  2004).  Sema4D/plexin-B1  induces 
phosphorylation  of  ErbB-2  and  subsequent  plexin-B1  phosphorylation.  The  tyrosine 
residues 1139 and 1248 on ErbB-2 are phosphorylated in response to Sema4D, while 
tyrosines  1112, 1139,  and 1248 are  activated through ErbB-1/ErbB-2  heterodimer by 
EGF.  The  Sema4D-induced  phosphorylation  of  ErbB-2  requires  plexin-B1,  whereas 
EGF-induced  activation  of  ErbB-2  does  not  have  the  ability  to  activate  plexin-B1. 
Therefore, Sema4D indirectly activates the tyrosine kinase of ErbB-2 and the subsequent 
autophosphorylation  of  ErbB-2  induces  plexin-B1  activation.  Grb  2  and  Shc  are  two 
substrates  of  ErbB-2  and  are  activated  through  binding  to  phosphorylated  tyrosine 
residues  1139  and  1248.  Phosphorylated  Shc  then  mediates  ErbB-2-dependent  Erk 
activation. Sema4D is found to activate Shc and Erk downstream of ErbB-2. ErbB-2 
mutated of its cytoplasmic tyrosine kinase activity totally blocks Sema-4D-induced RhoA 
activation  through  plexin-B1/PDZ-RhoGEF,  however  Erk  activation  downstream  of 
ErbB-2 is not required for RhoA activation. Interestingly, activated ErbB-2 by EGF does 
not  initiate  plexin-B1  phosphorylation  and  RhoA  activation  in  response  to  Sema4D. 
ErbB-2 expression is  found in  axonal  growth  cones  of primary hippocampal neurons 
cultured from rat embryos and staining with antibody against phosphorylated tyrosine 
1248 reveals that Sema4D-induced activation of ErbB-2 occurs in the central region of 
the  growth  cones.  ErbB-2  deleted  of  its  tyrosine  kinase  completely  abolishes  plexin-
B1/PDZ-RhoGEF-mediated growth cone collapse in hippocampal neurons. Thus ErbB-2 
is critically involved in Sema4D-induced plexin-B1 activation and subsequent signalling 
process through RhoA activation. 61 
 
  Activation of RhoA via plexin-B1/PDZ-RhoGEF requires ErbB-2, while Met is 
required for RhoA inactivation. ErbB-2 and Met have pro-migratory and anti-migratory 
effects, respectively, based on the investigation on breast cancer cell lines MCF-7 and 
MDA-MB-468  (Swiercz  et  al.,  2008).  Exchange  of  ErbB-2  and  Met  is  sufficient  to 
convert the cellular response to  Sema4D  from pro- to  anti-migratory  and vice versa. 
These findings on regulatory role of Met on cell motility in context with plexin-B1 by 
Swiercz group are contradictory to the report of Giordano et al. (Giordano et al., 2002; 
Swiercz et al., 2008). The controversial role of Met might depend on cell types and other 
factors involved in plexin-B1 signalling. The discussion about this point will be provided 
in the introduction and discussion part in Chapter 4. 
 
1.3.10 PI3K/Akt, PYK2, Src, MEK, and MAPK 
  It has been discussed in section 1.3.4 that the PI3K/Akt pathway is suppressed 
upon Sema4D activation via the R-RasGAP activity of plexi-B1 in hippocampal neurons. 
In contrast Swiercz and his colleagues have shown Akt is activated via plexin-B1/ErbB-
2-mediated  Rho  activation  (Swiercz  et  al.,  2004).  PI3K/Akt  pathway  has  also  been 
reported to be activated in response to Sema4D in endothelial cells and its activation is 
required  for  Sema4D/plexin-B1-mediated  cell  migration  (Basile  et  al.,  2005). 
Sema4D/plexin-B1-mediated activation of PI3K/Akt pathway is dependent on PYK2 and 
Src.  PYK2  is  a  tyrosine  kinase  member  of  FAK  family.  Upon  Sema4D  stimulation, 
PYK2 is phosphorylated at its tyrosine residues 579, 580 and 881 leading to the relief of 
autoinhibition and consequent activation of PYK2. Src is often functionally associated 62 
 
with  FAK  family  members  and  in  context  with  Sema4D/plexin-B1  signalling  Src  is 
phosphorylated on tyrosine 416. In consequence, PI3K becomes tyrosine phosphorylated 
on its p85 regulatory subunit and Akt is also activated. The activation of PI3K/Akt is Src-
dependent and inhibition of Src enzymatic activity abolishes PI3K/Akt phosphorylation 
in response to Sema4D. On Sema4D binding, receptor plexin-B1 is also phosphorylated 
and activated. PYK2 has been reported to be required for plexin-B1 activation; however, 
Src  is  not  necessary  for  plexin-B1  activation  despite  its  indispensible  role  in 
Sema4D/plexin-B-mediated PI3K/Akt pathway signalling and subsequent endothelial cell 
migration. In fact PYK2 signals upstream of plexin-B1 activation. PYK2 associates with 
plexin-B1  after  receptor  stimulation  and  initiates  plexin-B1  phosphorylation  and  Src-
regulated  cascade  activation  of  PI3K/Akt.  In  addition,  the  p85  subunit  of  PI3K  also 
associates with plexin-B1 soon after plexin-B1 stimulation and Src also associates with 
plexin-B1 in a complex. Therefore, Sema4D/plexin-B1 signalling pathway recruits PI3K 
and Src and activates PI3K/Akt pathway, resulting in endothelial cell migration. 
  The MAPK (mitogen-acitvated protein kinase) pathway is activated in response to 
Sema4D. In both endothelial cells and hippocampal cells expressing endogenous plexin-
B1, MEK and its downstream kinase ERK both exhibit increased phosphorylation level 
in response to Sema4D stimulation (Aurandt et al., 2006; Basile et al., 2007; Swiercz et 
al., 2008). The activation of MAPK pathway requires Ras, which co-operates with Rho to 
activate Raf and downstream MAPK. The mechanism underlying the role of Ras and Raf 
in Sema4D/plexin-B1-mediated MAPK needs to be elucidated with more evidence. 63 
 
  The PDZ-RhoGEF/LARG-mediated RhoA activation is required for either PYK2-
regulated activation of PI3K/Akt pathway or activation of MAPK pathway. In endothelial 
cells, Sema4D/plexin-B1 signalling initiates the actomyosin cytoskeleton reorganization 
through RhoA and ROK leading to promotion of integrin-dependent assembly of focal 
adhesion, which results in cell adhesion and facilitates cell migration. The focal adhesion 
complexes associate with PYK2 which in turn activate PI3K/Akt pathway in response to 
Sema4D.  This  observation  of  pro-migratory  effect  of  Sema4D/plexin-B1  through 
activation  of  PI3K/Akt  pathway  in  endothelial  cells  is  opposite  to  the  report  that 
Sema4D/plexin-B1 inhibits migration and adhesion through suppression of PI3K by the 
Japanese group. The difference is possibly due to different cell types. On the other hand, 
MAPK pathway activation by Sema4D/plexin-B1 signalling is also abolished in cells in 
which  PDZ-RhoGEF-mediated  RhoA  activity  has  been  inhibited,  indicating  the 
requirement of RhoA activity in MAPK activation. 
 
1.4 Plexin-B1 mutations in prostate cancer 
  Previously our group have reported plexin-B1 mutations in both prostate cancer 
cell lines and clinical samples of prostate cancer (Wong et al., 2007). Over-expression of 
plexin-B1 protein in primary prostate cancers was also observed. Using SSCP analysis, 
we screened  exons  22-29 of the cytoplasmic domain of the plexin-B1 in  DNA from 
tumor  tissues.  Mutations  were  detected  in  89%  (8  of  9)  of  prostate  cancer  bone 
metastases, in 41% (7 of 17) of lymph node metastases, and in 46% (41 of 89) of primary 
prostate tumors. Among all the mutations, some mutations are present in relatively higher 64 
 
frequency. A5653G (Thr1795Ala) is present in 9 of 26 (35%) metastases and 38 of 89 
(43%) primary cancers. T5714C (Leu1815Pro) is found in three metastases and in two 
primary tumors. A single nucleotide change (A5359G) in plexin-B1 in LNCaP changes 
threonine 1697 to  an alanine. This  mutation is  present  in  two of the three  copies of 
chromosome 3p in LNCaP cells. Previous studies on these three mutants revealed that the 
mutations altered the function of the plexin-B1 protein, increasing cell invasion, adhesion, 
and lamellipodia extension and decreasing collapse relative to wildtype plexin-B1 (Wong 
et al., 2007). The mutations inhibit or hinder Rac1 and R-Ras GTP binding and R-Ras 
GAP  activity.  Table  1.1  summaries  the  alterations  of  protein  interaction  of  the  three 
mutated forms relative to the wildtype plexin-B1. 
Table 1.1 Protein function changes of the plexin-B1 mutations relative to wildtype 
  Rac 
binding 
Rnd 
binding 
R-Ras  
binding 
RhoD 
binding 
ErbB-2 
binding 
Met 
binding 
PDZ-RhoGEF 
binding 
wt  binds  binds  binds  unknown  binds  binds  binds 
A5359G  reduced  binds  lost  unknown  unknown  unknown  binds 
A5653G  reduced  binds  lost  unknown  unknown  unknown  binds 
T5714C  lost  lost  lost  unknown  unknown  unknown  binds 
 
However, it is not yet known whether the mutations have any effect on the coupling of 
plexin-B1 to receptor tyrosine kinases such as ErbB-2 and Met. It is also not clear that if 
RhoD binding is altered by the mutations, given the fact that the mutated sites are located 
withing the GTPase binding region. Therefore, my study aims to find answers to these 65 
 
unknow questions and to further explore the effects of mutations on cell signalling and 
cell function. 
 
Hypothesis 
  Based on the previous finding that plexin-B1 mutations are highly frequent in 
primary  and  metastatic  prostate  cancer  and  the  mutations  alter  protein  functions,  I 
hypothesized  that  plexin-B1  mutations  play  an  important  role  in  prostate  cancer 
progression through exerting effects on cell signalling and subsequently cell functions. 
The signalling pathways affected by plexin-B1 mutations may be (1) interaction with 
non-receptor/receptor tyrosine kinases such as Met, ErbB-2 and MAPK; (2) interaction 
with small GTPases such as RhoD. These pathways on top of other altered features by 
plexin-B1 mutations, e.g. R-Ras GAP activity, Rac1 binding ability, will contribute to the 
increased motility characteristic of plexin-B1 mutants. 
 
Aim 
  The aim of this project was to characterize the effects of the three mutated forms 
of plexin-B1, A5359G, A5653G and T5714C, on cell signalling and cell functions. 
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Objectives 
  The objectives were to determine if mutation of plexin-B1 (1) alters interaction of 
plexin-B1 with Met; (2) alters interaction with ErbB-2; (3) alters interaction with RhoD; 
(4) affects motility of prostate cancer cells. 
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Chapter 2 
Materials and Methods 
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2.1 Cell culture 
All cell lines were maintained at 37C, 5% CO2 in T-25 flasks. Cell lines LNCaP, 
DU145, PC3, PC3-LN3, 22RV1, 1532NPT, 1542CPT and 1542NPT were maintained in 
RPMI1640 (Invitrogen)  supplemented with  8% fetal bovine serum (FBS, Invitrogen). 
Cell  lines  HEK293,  MCF7  and  COS7  were  cultured  with  DMEM  (Invitrogen) 
supplemented  with  8%  FBS.  PC12  cells  were  maintained  in  RPMI1640  medium 
supplemented with 10% horse serum. 
Table 2.1 Cell line information 
Name  Disease  Source  Species  Metastatic site 
LNCaP  carcinoma  prostate  human  lymph node 
DU145  carcinoma  prostate  human  brain 
PC3  adenocarcinoma  prostate  human  bone 
PC3-LN3  adenocarcinoma  prostate  human  lymph node 
22RV1  carcinoma  prostate  human  N/A 
1532NPT  benigh  prostate  human  N/A 
1542CPT  carcinoma  prostate  human  N/A 
1542NPT  benign  prostate  human  N/A 
HEK293  N/A  embryonic kidney  human  N/A 
MCF7  adenocarcinoma  mammary gland  human  pleural effusion 
COS7  N/A  kidney  monkey  N/A 
PC12  pheochromocytoma  adrenal gland  rat  N/A 
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2.2 RNA extraction 
 RNA  was  extracted  according  to  the  manufacturer’s  instructions  using  the 
RNeasy Mini Kit (Qiagen). 80% confluent cells (no more than 1 ×  10
7 cells) were washed 
with PBS (Invitrogen) and detached from culture flasks using tyrpsin (Invitrogen). Cells 
were centrifuged and collected as cell pellets in eppendorfs. Cells were loosen by flicking 
and then lyased in 350 µl of Buffer RLT with β-ME (β-Mercaptoethanol) supplied by the 
Kit.  The  lysate  was  mixed  by  pipeting  and  loaded  onto  a  QIAshredder  spin  column 
placed in a 2 ml collection tube, and centrifuged for 2 minutes at 13,000 rpm. An equal 
volume of 70% ethanol was then loaded onto an RNeasy mini column placed in a 2 ml 
collection tube and centrifuged for 15 seconds  at 13,000 rpm. The flow-through was 
discarded. 700 µl of Buffer RW1 (supplied by the Kit) was added to the RNeasy column 
and centrifuged for 15 seconds at 13,000 rpm. The flow-through was  discarded after 
centrifuge. Columns were then washed twice with Buffer RPE (supplied by the Kit) by 
centrifuge for 15 seconds at 13,000 rpm. RNA in the RNeasy column was then eluted 
using 30-50 µl of RNase-free water. RNA samples were stored at -70C. 
 
2.3 RT-PCR 
  All the procedures were performed using RNase free eppendorfs and tips. The 
first-strand  cDNA  was  synthesized  using  SuperScript  II  RT  (Invitrogen)  at  room 
temperature. RNA samples were mixed with Oligo (dT) and dNTP Mix, diluted to the 
appropriate volume in RNase free H2O. The mixture was heated to 65C for 5 minutes, 70 
 
followed by quick chilling on ice. Appropriate quantities of 5 ×  First-strand buffer and 
0.1M DTT were added to the mixture and mixed gently. The mixture was incubated at 
42C for 2 minutes. 1 µl of SuperScirp
TM II Reverse Transcriptase was added to the 
mixture and incubated at 42C for 50 minutes. The reaction was inactivated by heating at 
70C for 15 minutes. The synthesized cDNA was ready for PCR or stored at -20C. 
Primers   
GAPDH  5’-CCACCCATGGCAAATTCCATGGCA-3’ 
GAPDH antisense  5’-TCTAGACGGCAGGTCAGGTCCAC-3’ 
Sema4D  5’-CGCCCACAGCGACCTGCGTG-3’ 
Sema4D antisense  5’-GACATGAGGAGGCGGTTGTC-3’ 
Plexin-B1  5’-TGCCGCTCGCTGTGAAGTAC-3’ 
Plexin-B1 antisense  5’-CCACAGCAGCTGCAATCTGC-3’ 
 
PCR reactions 
95C  1 minute 
95C  50 seconds 
60C  50 seconds          28 cycles 
68C  1 minute 
68C  7 minutes 71 
 
2.4 Agarose electrophoresis for DNA 
  DNA products were analyzed by agarose gel electrophoresis. 1% agarose gel was 
set by heat dissolving 1 g of agarose mixed with 100 0.5 ×  ml Tris-borate-EDTA (TBE, 
90mM Tris-borate, 2mM EDTA, pH8.3) buffer. 2 µo of ethidium bromide (0.5 µg/ml) 
was added before the gel was set. DNA samples were mixed with 6 ×  DNA loading dye 
(0.25  bromophenol  blue,  0.25%  xylem  cyanol  FF,  30%  glycerol)  to  make  the  find 
concentration of 1 ×  of loading dye. 0.5 µg of 1kb Plus DNA ladder (Invitrogen) was 
loaded as the marker for DNA sizes. Electrophoresis was carried out in TBE buffer in the 
electrophoresis  unit  Electro-4Gel  Tank  (Thermo  Electron  Corporation)  at  150  V  for 
around one hour. The DNA in complex with ethidium bromide was visualized using UV 
transilluminator (Gene Genius, Bio Imaging System). 
 
2.5 Plasmid constructs 
  The vector maps are presented in Appendix 1. Constructs expressing Met and 
VSV-plexin-B1 wildtype were gifts from Dr. Luca Tamagnone (University of Torino 
School  of  Medicine,  Italy).  Plasmids  encoding  constitutively  active  RhoD  pEF-
BOS/Myc-RhoD  (G26V)  and  dominant  negative  RhoD  pEF-BOS/Myc-RhoD  (T31K) 
were  generously  provided  by  Professor  Takeshi  Endo  (Chiba  University,  Japan). 
Constructs  expressing  VSV-tagged  plexin-B1mutants  and  GST-cyto-plexin-B1 
WT/mutants were from previous group member Dr. Oscar Wong. Constructs encoding 72 
 
Sema4D fused to human IgG1 Fc fragment was provided by Dr. Hitoshi Kikutani (Osaka 
University, Japan). 
 
2.6 Transformation of E. Coli 
  Subcloning  Efficiency
TM  DH5α
TM  Competent  cells  (Invitrogen)  were  used  for 
transformation. 0.25 µg of plasmids was mixed with 50 µl of competent cells gently and 
the mixture was then incubated on ice for 20 minutes. After the incubation the mixture 
was heat-shocked at 42C for 1 minute and followed by 2 minutes incubation on ice. 300 
µl of S.O.C. medium (Invitrogen) was added to the cells and the mixture was incubated at 
37 C for one hour. After the incubation, 80 to 100 µl of the mixture was spread on a LB 
agar plate supplemented with the appropriate selective antibiotic (ampicillin, 50 µg/ml ). 
The plate was then incubated at 37C overnight and colonies were picked the next day. 
 
2.7 DNA purification 
  Plasmid DNA was purified using the QIAGEN Plasmid Maxi Kit (Qiagen) at 
large scale. One single colony was picked from the overnight LB agar plate described in 
previous paragraph and inoculated into 2-5 ml of LB medium supplemented with the 
appropriate selective antibiotic. The starter culture was then incubated at 37 C for 8 
hours with vigorous shaking at 300 rpm. The starter culture was then diluted 1/500 to 
1/1000 (100 ml or 500 ml) with selective LB medium. The culture was then incubated at 73 
 
37 C for 12-16 hours with vigorous shaking at 300 rpm. Bacterial cells were collected 
by centrifugation at 6,000 g for 15 minutes at 4 C and then resuspended in 10 ml Buffer 
P1 (supplemented with RNase A which was supplied by the Kit). Until the cells were 
evenly suspended, 10 ml of Buffer P2 (supplied by the Kit) was added and mixed by 
inverting 4-6 times. The mixture was incubated at room temperature for 5 minutes. After 
that 10 ml of chilled Buffer P3 (supplied by the Kit) was added immediately and mixed 
gently by inverting 4-6 times. The mixture was incubated on ice for 20 minutes. At the 
end of incubation, the mixture was centrifuged at 20,000 g at 4C for 30 minutes and the 
supernatant was collected. The supernatant was further cleared by another centrifugation 
at 20,000 g for 15 minutes at 4 C. The DNA containing supernatant was then applied to 
a QIAGEN-tip 500 that was equilibrated with 10 ml of Buffer QBT (supplied by the Kit). 
The supernatant was allowed to enter the resin by gravity flow. The QIAGEN-tip was 
then washed with two portions of 30 ml of Buffer QC (supplied by the Kit) by gravity 
flow.  DNA  was  eluted  with  15  ml  of  Buffer  QF  (supplied  by  the  Kit)  and  then 
precipitated by mixing with 10.5 ml of room temperature isopropanol. Immediately the 
mixture was  centrifuged at  15,000  g for 30 minutes at  4C. After the centrifuge the 
supernatant was removed. The DNA pellet was washed with 5 ml of room temperature 
70% ethanol and centrifuged at 15,000 g for 10 minutes. The supernatant was removed 
and the pellet was left for air-dry for 5-10 minutes. The DNA was then dissolved in a 
suitable  volume  of  TE  buffer,  pH  8.0  and  DNA  concentration  was  measured  by 
spectrophotometry  at  a  wavelength  of  260nm/280nm  using  UV/Visible 
Spectrophotometer Ultrospec 3100 Pro. 74 
 
2.8 Lipofectamine transfection 
  The ratio of DNA (µg) to Lipofectamine
TM 2000 (µ l, Invitrogen) was dependent 
on the size of the culture flasks used. The details of different scales of transfection were 
listed in Table 2.2. The following protocol describes the transfection procedure in 6-well 
plates. One day before transfection, cells were plated in 2 ml of growth medium so that 
cells would be 95% confluent at the time of transfection. For each well, 4 µg of plasmid 
constructs  was  diluted  in  250  µl  of  Opti-MEM
®I  medium  (Invitrogen).  10  µl  of 
Lipofectamine
TM 2000 was diluted in 250 µl of Opti-MEM
®I medium and was incubated 
for 5 minutes at room temperature. After the incubation, the diluted DNA was mixed 
gently with diluted Lipofectamine
TM 2000 to give a total volume of 500 µ l. The mixture 
was then incubated for 20 minutes at room temperature and added to the well containing 
cells and medium. Cells were incubated with the Lipofectamine-DNA complex for 4 
hours and fresh medium was added. Cells were incubated for 24-48 hours before further 
study. 
Table 2.2 Scaling up or down transfections 
Culture vessel  Surface area 
per well 
Volume of dilution 
medium 
DNA  Lipofectamine
TM 
2000 
6-well  10 cm
2  2 × 250 µl  4.0 µg  10 µl 
60-mm  20 cm
2  2 × 250 µl  8.0 µg  20 µl 
10-cm  60 cm
2  2 × 250 µl  24 µg  60 µl 
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2.9 Protein extraction 
  Cells ready for protein extraction were washed with cold 1 ×  PBS quickly and 
lysed in appropriate volume of modified radioimmunoprecipitation (RIPA) buffer [50 
mM Tris-HCl, pH 7.4, 1% TritonX-100, 150 mM NaCal, 1 mM EDTA, 1 mM NaF, 1  
mM Na3VO4, 1 protease inhibitor cocktails tablet per 10 ml of RIPA buffer (Roche)]. 
Cells were then scraped off using cell scraper (BD) and the cell lysate was transferred 
into  a  1.5  ml  eppendorf  tube.  The  lysates  were  left  on  ice  for  15  minutes  and  then 
centrifuged at 13,000 rpm for 15 minutes at 4C. After the centrifuge the supernatant was 
collected in a pre-chilled eppendorf tube and ready for subsequent study or could be 
stored at -80C. 
 
2.10 Protein concentration measurement 
  The total protein concentrations of lysates extracted from cells were measured 
using Modified Lowry Protein Assay Kit (PIERCE). Serial dilutions of Bovine Serum 
Albumin (BSA) were made from the BSA standard solution (2 mg/ml, supplied by the 
Kit) as listed in Table 2.3, 76 
 
Table 2.3 BSA standards preparation 
Volume of standard 
solution (µl) 
Distilled water (µl)  Final concentration (µg/ml) 
0  200  0 
1.56  198.44  15.63 
3.13  196.87  31.25 
6.25  193.75  62.5 
12.5  187.5  125 
25  175  250 
50  150  500 
 
  10 µl of each lysate sample was diluted 20 folds with 190 µl of distilled water. 1 
ml of Modified Lowry Protein Assay Reagent was added to each diluted sample or BSA 
standard and mixed gently. The mixture was incubated for exactly 10 minutes at room 
temperature. 2N Folin-Ciocalteu Reagent (supplied by the Modified Lowry Protein Assay 
Kit) was diluted 1/2 with distilled water to make the concentration of 1N. At the end of 
the 10 minute incubation, 100 µl of 1N Folin-Ciocalteu Reagent was added to each lysate 
sample or BSA standard and mixed gently. The mixture was incubated for 30 minutes at 
room  temperature.  Afterwards,  the  samples  were  measured  using  the  UV/Visible 
Spectrophotometer Ultrospec 3100 Pro. Standard curve was plotted automatically by the 
machine  based  on  absorbance  readings  against  the  concentrations  of  BSA  standards. 
Readings  of  lysate  samples  were  taken  from  the  machine  and  concentrations  were 
calculated by ×  20 of the values from the machine. 77 
 
2.11 SDS-PAGE and protein blotting 
  Equal amount of total protein from lysate samples was normalized to the same 
volume using RIPA buffer. Appropriate volume of 6 ×  Sample Buffer (200 mM Tris, 
pH6.8, 60% glycerol, 12 mM  EDTA, 12% SDS, 864 mM β-mercaptoethanol, 0.05% 
bromophenol blue) was added to the protein samples to reach the final concentration of 1 
×  SB. The mixture was heated at 95C for 5 minutes. The denature protein samples were 
then ready to be loaded onto the sodium dodecyl sulphate (SDS)-polyacrylamide gel with 
appropriate concentration of acrylamide, depending on the size of the protein investigated. 
The recipe of SDS-polyacrylamide gel is listed in Table 2.3.  
Table 2.4 Recipe of SDS-polyacrylamide gel 
Resolving gel 
  6%  8%  10%  12%  14% 
1 M Tris, pH8.8  3.75 ml  3.75 ml  3.75 ml  3.75 ml  3.75 ml 
30% Acrylamide  2 ml  2.67 ml  3.33 ml  4 ml  4.67 ml 
H2O  4.2 ml  3.53ml  2.87 ml  2.2 ml  1.53 ml 
20% SDS  50 µl  50 µl  50 µl  50 µl  50 µl 
10% (APS)  100 µl  100 µl  100 µl  100 µl  100 µl 
TEMED  6 µl  6 µl  6 µl  6 µl  6 µl 
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Table 2.4 Recipe of SDS-polyacrylamide gel (continued) 
Stacking gel     
1 M Tris, pH 6.8  375 µl   
30% Acrylamide  374 µl   
H2O  2.24 ml   
20% SDS  15 µl   
10% APS  30 µl   
TEMED  5 µl   
 
  For  one  SDS-polyacrylamide  gel,  around  8  ml  of  resolving  gel  solution  was 
poured  into  the  assembled  Mini-PROTEAN  III  (Bio-Rad)  gel  cassette.  When  the 
resolving gel was set, stacking gel solution was prepared and pored onto the top of the 
resolving gel. The comb was place into the stacking gel before the gel was set. When the 
whole gel was set, boiled protein samples were applied to the separated wells. 10 µl of 
Rainbow  Molecular  Weight  Marker  (Amersham)  was  loaded  as  the  reference  for 
molecular sizes. The gel was subjected to electrophoresis using the Mini PRTOTEAN III 
Electrophoresis System (Bio-Rad) at a constant current (20 mA per gel) in running buffer 
(25 mM Tris, 0.19 M glycine, 0.1% SDS) for 1-2 hours until the dye was running out 
from the bottom of the gel. 
 79 
 
2.12 Western-blotting 
  Immediately after the SDS-PAGE, proteins on the SDS-polyacrylamide gel were 
electronically transferred onto a Polyvinylidene fluoride (PVDF) membrane (Millipore). 
The transfer sandwich, including the spone, filter paper, gel and PVDF membrane, was 
assembled as illustrated below, 
 
 
Every component of the transfer sandwich was rinsed in transfer buffer (25 mM 
Tris,  HCl,  192  mM  glycine,  20%  methonaol).  The  PVDF  membrane  was  pre-wet  in 
100% methanol for 15 seconds and then rinsed in transfer buffer. The transfer sandwich 
was place into the assembly tray of the Mini Trans-Blot Cell (Bio-Rad) which was filled 
with transfer buffer. The gel was closed to the cathode and the electrotransfer was carried 
out at a constant voltage of 20 V overnight at 4C. 
  After electrotransfer, the membrane was rinse briefly in PBS-Tween 20 (PBS-T, 
0.1% Tween-20 in 1 ×  PBS) and blocked in 5% non-fat milk (in PBS-T) for 1 hour at 
room temperature. After blocking, the membrane was probed with 5 ml of appropriately 
diluted primary antibody (the details of antibodies used all through are listed in Table 2.4) 
in 1% non-fat milk (in PBS-T) and incubated for 1-2 hours at room temperature or over-
night at 4 C. After primary antibody incubation, the membrane was washed with PBS-T 80 
 
for  2  minutes  four  times.  After  washing  the  membrane  was  incubated  with  5  ml  of 
appropriate horseradish peroxidase (HRP)-conjugated secondary antibody diluted in 1% 
non-fat milk (in PBS-T) for 1 hour. The membrane was then washed with PBS-T for 2 
minutes four times and ready for enhance chemiluminescent (ECL) development. 
  The chemiluminescent signals were developed by Pierce ECL Western Blotting 
Substrate (PIERCE). Appropriate volume of mixture of Detection Reagents 1 and 2 at a 
1:1 ratio was added to the membrane and incubated for 5 minutes at room temperature. 
The membrane was then placed between two sheets of transparency and set into a Kodak 
BioMax Cassette (Kodak). The membrane was exposed to X-ray films and the films were 
developed with developer and fixer solutions (Kodak). 
Table 2.5 Antibody list 
Against antigen  manufacturer  Catalogue no.  Dilution factor 
Plexin-B1  Santa Cruz  sc-25642  1:1000 
VSV tag  Sigma  V4888  1:1000 
myc tag  Sigma  C3956  1:5000 
plexin-B1 (C-terminal)  ECM  PP1841  1:1000 
ErbB-2  Upstate  06-562  1:5000 
Met  Santa Cruz  sc-161  1:1000 
phospho-MEK1/2  Cell signaling  9154  1:1000 
phospho-p44/42MAPK  Cell signaling  4377  1:1000 
Akt  Cell signaling  9272  1:1000 
phospho-Akt  Cell signaling  9271  1:1000 
MEK1/2  Cell signaling  9122  1:1000 81 
 
2.5 Antibody list (continued) 
CD100  BD  61060  1:2000 
beta-actin  Abcam  ab6276  1:5000 
anti-Rabbit IgG-HRP  Santa Cruz  sc-2004  1:5000 
anti-mouse IgG-HRP  Santa Cruz  sc-2005  1:5000 
 
 
2.13 Immunoprecipitation 
  HEK293 cells were transfected with appropriate plasmids and cells were lysed as 
described in previous sections. 1 mg of total protein for each sample was used for each 
immunoprecipitation assay. Each sample lysate was normalized to the same volume of 1 
ml. Sample lysate was then precleared by incubating with 20 µl of Protein A agarose 
slurry (Invitrogen) by rotation at 4C for 1 hour. The lysate was centrifuged at 12,000 
rpm for 20 seconds and the supernatant was collected into a fresh eppendorf tube. 1 µg of 
selective antibody against the targeted antigen was added into the precleared lysate and 
incubated for 3 hours at 4C. the antigen-antibody complex was then mixed with 50 µl of 
Protein-A agarose and incubated overnight at 4C on a rocking platform. At the end of 
incubation, the antibody-sample complex with agarose was centrifuged at 12,000 rpm for 
20 seconds at 4C and the supernatant was removed by vacuum. The precipitated beads 
were then washed one with RIPA lysis buffer at 12,000 rpm for 20 seconds at 4C. The 
second wash was carried out with high salt wash buffer (50 mM Tris-HCl, pH7.5, 500 
mM NaCal, 0.1% TritonX-100) and the third wash was performed with low salt buffer 82 
 
(50 mM Tris-HCl, pH7.5, 0.1% TritonX-100). After the wash, the agarose beads were 
pelleted and the last trance of wash buffer was removed. 40 µl of 1 ×  Sample Buffer was 
added to the bead pellet and mixed well gently. Proteins on the bound to the beads were 
released by heating at 95% for 5 minutes. Samples were centrifuged and the supernatants 
were collected and ready to be analyzed by SDS-PAGE and immunoblotting. 
 
2.14 Coomassie blue staining of SDS-polyacrylamide gel 
  At the end of SDS-PAGE, the SDS-polyacrylamide gel was fully immersed in the 
appropriate  volume  of  Coomassie  Plus  Reagent  (PIERCE)  and  incubated  with  mild 
shaking at room temperature for at least 1 hours. The stained gel was destained with 
distilled water for a couple of hours until blue protein bands were observed with good 
contrast  with  the  blank  gel.  The  gel  was  dried  and  preserved  using  Gel  Drying  Kit 
(Promega). Gel was soaked in gel drying solution (40% methanol, 10% glycerol, 7.5% 
acetic  acid)  for 3-5 minutes. Two sheets  of Gel Drying Film  (Promega) were rinsed 
briefly in the gel drying solution. After that the gel was placed in between of the two 
sheets and the films were clamped on the Gel Drying Frames and were left air-dry.  
 
2.15 Inducing competence and transforming of BL21 
  The  E.  coli  BL21  strain  (Amersham)  was  used  for  expression  of  GST  fusion 
proteins.  Firstly  BL21  cells  were  induced  of  competence.  Lyophilized  culture  was 
resuspended in 1 ml of L-broth and grown overnight with shaking at 300 rpm at 37C. the 83 
 
overnight culture was then spread onto a L-broth medium plate and incubated for 12-16 
hours at 37C until colonies were formed. One single colony was picked and inoculated 
into 5 ml of LB medium and incubated overnight at 37C with vigorous shaking at 300 
rpm.  4  ml  of  the  overnight  culture  was  inoculated  into  400  ml  of  LB  medium  and 
incubated at 37C with vigorous shaking at 300 rpm until OD590 was above 0.375. The 
culture  was  divided  into  eight  portions  and  transferred  into  50  ml  pre-chilled  tubes, 
followed by incubation on ice for 10 minutes. Bacterial cells were collected by centrifuge 
at 1,600 g for 7 minutes at 4C. The cell pellets were re-suspended in 10 ml of ice-cold 
CaCl2  solution  (60  mM  CaCl2,  15%  glycerol,  10  mM  PIPES)  and  washed  twice  by 
centrifuge at 1,600 g for 7 minutes at 4C. After washing steps, cells were suspended in 
10 ml of ice-cold CaCl2 solution and incubated on ice for 30 minutes. The bacterial cells 
were then precipitated by centrifuge at 1,100 g for 5 minutes at 4C and the cell pellets 
were suspended in 2 ml of ice-cold CaCl2 buffer. The competent BL21 cell solution was 
then divided into aliquots at 250 µl and stored at -80C. 
  For transformation of BL21 cells with plasmids, 0.5 µg of plasmids was mixed 
gently with 250 µl of competent BL21 cells. The mixture was incubated on ice for 20 
minutes and heat-shocked at 42C for 1 minute. 300 µl of S.O.C. medium was then added 
to the bacterial cells and incubated at 37C for 1 hour. 80-100 µl of the transformed cells 
was spread onto LB agar plates containing appropriate selective antibiotics (Ampicillin, 
50 µg/ml, Sigma). The LB agar plates were incubated overnight at 37C until colonies 
formed. 
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2.16 GST-cyto plexin-B1 purification 
  Plasmids  pGEX-4T3  encoding  GST-fused  cyto-plexin-B1  wildtype  or  mutants 
were from previous group member Oscar Wong and described in his thesis. Competent 
BL21 cells were transformed with pGEX-cytoB1 WT/mutants as described in previous 
section. One single colony was inoculated into 200 ml of LB broth medium (ampicillin, 
50 µg/ml) and incubated at 37C with vigorous shaking at 300 rpm until OD600 reached 
0.6. Fusion protein expression was induced by adding 200 µl of 100 mM isopropyl β-D-
thiogalactoside (IPTG) and the bacterial culture was incubated for additional 2 hours. The 
induced culture was centrifuged at 7,700 g for 10 minutes at 4C and cell pellets were 
then lysed with 10 ml of CelLytic
TM B buffer (Sigma) supplemented with 0.2 mg/ml 
lysozyme  (Sigma),  50  µg/ml  DNaseI  (Sigma),  1  mM  dithiothreitol  (DTT),  10  µg/ml 
aprotinin,  10  µg/ml  leupeptin,  and  1  mM  phenylmethylsulfonyl  fluoride  (PMSF).  In 
alteration, cell pellets were lysed in 10 ml of lysis buffer (50 mM Tris, pH7.5, 1% Triton 
X-100, 150 mM NaCl, 5 mM MgCl2, 1 mM DTT, 10 µg/ml aprotinin, 10 µg/ml leupeptin, 
and 1 mM PMSF. The lysed cells could be subjected to sonication on ice with a setting at 
50% amplitude for six to eight times, 15 sec each using Sonic Vibra Cell. Lysed samples 
were kept on ice for 1-2 minutes between sonications. 
  The lysate was clarified by centrifugation at 14,000 rpm for 30 minutes at 4C 
and the supernatant was collected. The supernatant containing the fused protein was then 
mixed with 200 µl of 50% slurry of Glutathione Sepharose 4B (Amersham) equilibrated 
with 1 ×  PBS and incubated on rotation overnight at 4C. The matrix was centrifuged at 
500 g for 5 minutes at 4C and the supernatant was removed. The matrix was washed five 85 
 
times with 1 ml of cold 1 ×  PBS by centrifuge. The matrix containing the GST-fused 
protein was then resuspended in 100 µl of 1 ×  PBS and used for GST-pull down assay. 
The matrix was stored at 4C. 10 µl of the matrix was analyzed by SDS-PAGE (8% SDS-
polyarylamide gel) and Coomassie blue staining to check the yield of GST-fused protein 
expression.  
 
2.17 GST-pull down assay 
  Cell lysate expressing the target protein for interaction study was incubated with 
20 µl of the matrix obtained in section 2.16 overnight with rotation at 4C. The matrix 
was washed four times with cold 1 ×  PBS by centrifuge at 500 g for 5 minutes at 4C. 
The supernatant was decanted and the sepharose beads were resuspended in 20 µl of 1 ×  
sample buffer. Samples were heated at 95C for 5 minutes and ready for analysis by 
SDS-PAGE and Western-blotting. 
 
2.18 Generation and purification of Sema4D 
  COS7  cells  were  grown  to  60%  confluence  in  T-75  culture  flasks  and  were 
transfected with plasmid encoding Sema4D-Fc using the Lipofectamine
TM 2000 reagent. 
Cells were incubated in DMEM supplemented with 8% of low IgG FBS for 72 hours at 
37C for Sema4D-Fc secretion. Supernatant medium from 3 T-75 flasks was collected 
and  centrifuged  to  get  rid  of  cell  debris.  The  Sema4D-Fc  containing  medium  was 86 
 
incubated  with  2  ml  of  50%  slurry  of  Protein  A  Sepharose  (Sigma)  with  rotation 
overnight at 4C. Sepharose beads were precipitated by centrifuge and resuspended in 4 
ml of cold  1 ×  PBS. The bead matrix was  applied to  a PBS equilibrated disposable 
column (Falcon) and left to drain by gravity flow. The column was washed with 15 ml of 
cold 1 ×  PBS. Sema4D-Fc was eluted using 2.5 ml of 100mM glycine, pH2.7, neutralized 
in 500 µl of 1M Tris, pH9.0. The eluted Sema4D-Fc was transferred into Amicon Ultra-4 
Centrifugal filter Devices, 10K (Millipore) and concentrated by centrifuge at 3,000 rpm 
for 12 minutes. The Sema4D-Fac containing solute in the insert was collected and stored 
at -80C. The yield of Sema4D-Fc was analyzed by SDS-PAGE and Coomassie blue 
staining. 
  In alteration, COS-7 cells were transfected with plasmid encoding GST-Sema4D-
AP. After transfection and incubation, supernatant was clarified by centrifuge and applied 
to  the  matrix  in  a  drained  and  washed  Glutathione  Sepharose  4B  RediPack  (GE 
Healthcare). The lysate was allowed to flow through by gravity flow. The fusion protein 
bound on the matrix was washed twice with 10 ml of cold 1 ×  PBS. After washing step, 1 
ml  of  glutathione  elution  buffer  (provided  by  the  Kit)  was  added  to  the  matrix  and 
incubated for 10 minutes to elute the fusion protein. The elution step was repeated twice 
more  and  the  three  elutes  were  pooled  together.  The  GST-Sema4D-Fc  solute  was 
analyzed by SDS-PAGE and Coomassie blue for quality check. 
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2.19 Dialysis of Sema4D concentrates 
  Sema4D concentrate was dialyzed to remove low molecular weight contaminant 
by  using  Slide-A-Lyzer  Dialysis  Cassette  (Thermo  scientific).  The  Slide-A-Lyzer 
Cassette was hydrated in dialysis buffer 1 ×  PBS for 1-2 minutes. Sema4D concentrate 
was added to the cassette by syringe injection. The sample was dialyzed for 2 hour at 4C. 
After that the sample was dialyzed in fresh dialysis buffer for another 2 hours. Dialysis 
buffer was changed again and the dialysis was performed overnight at 4C. The dialysis 
buffer was at 200-500 times the volume of the sample. After dialysis, the sample was 
collected by syringe and stored at -80C. 
 
2.20 Migration assay 
  Migration assays were performed using Transwell
® Permeable Support System 
(Corning). Cells were serum starved overnight the day before migration assays and were 
detached from culture flasks using cell dissociation solution (Sigma). After dissociation 
step cells were suspended in culture medium without serum and 20,000 cells were seeded 
into each insert in the volume of 100 µl. The lower side of the inserts was coated with 15 
µg/ml fibronectin (Sigma) for 2 hours at 37 C before cell seeding. The wells of the lower 
plates were filled with the same culture medium as the inserts. Cells were incubated for 6 
hours in the absence or presence of Sema4D. At the end of incubation, cells on the upper 
side of the inserts were removed using cotton buds and the cells on the lower sides were 
fixed  with  freshly  prepared  4%  paraformaldehyde  for  15  minutes.  Fixed  cells  were 88 
 
stained with 0.5% crystal violet (in 20% ethanol) for 1 hour. The membrane was washed 
with distilled water and air dried. For each inserts, five different fields were randomly 
selected under the microscope at100 ×  magnifications and the cell numbers were counted. 
Relative cell migration was determined by the numbers of the migrated cells normalized 
to the number of control. Each experiment was repeated at least three times and the error 
bars indicated standard deviations. 
 
2.21 Statistical analysis 
For cell motility assays, P values were calculated using a two-Two-tailed Students 
t-test  when  comparing  values  of  controls  and  treatments.  p<0.05  was  considered 
statistically significant. 
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Chapter 3 
Plexin-B1 expression in cancer cells 
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3.1 Introduction 
Sema4D is expressed in a variety of tissues and organs, but strongly expressed 
mainly in lymphoid organs. In non-lymphoid organs, Sema4D is expressed at low levels. 
The receptor for Sema4D, plexin-B1, is reported to be ubiquitously distributed at mRNA 
level  (Maestrini  et  al.,  1996).  In  human  cancer  cell  lines  derived  from  colon,  liver, 
pancreas, and gastric tumors, plexin-B1 protein is over-expressed (Conrotto et al., 2004). 
Recently, our lab has also demonstrated that plexin-B1 and Semaphorin 4D were over-
expressed  in  primary  prostate  cancer  (Wong  et  al.,  2007).  There  is  no  report  on 
expression of plexin-B1 in prostate cancer cell lines. This chapter aimed to reveal the 
expression profiles of plexin-B1 and Sema4D in human prostate cancer cell lines at both 
mRNA and protein levels. A wide range of human cell lines derived from tumors and 
other  mammalian  cell  lines  were  also  screened  for  endogenous  plexin-B1  and 
Semaphorin 4D expressions at both mRNA and protein levels for a comparison. 
 
3.2 Results 
3.2.1 Expression of plexin-B1 and Sema4D at the mRNA level 
RNA  samples  extracted  from  different  cell  lines  were  reverse  transcripted  to 
synthesize  first  strand  cDNA  and  the  products  were  amplified  by  PCR  with  specific 
primers for target genes. Figure 3.1 shows the expression of plexin-B1 and Sema4D at 
the  mRNA  level.  All  the  human  prostate  cancer  cell  lines  DU145,  PC3,  LNCaP, 
1542CPT,  1532CPT,  human  benign  prostate  cell  line  1542NPT,  and  human  kidney 91 
 
embryonic  cells  HEK293  exhibited  plexin-B1  expression  at  the  mRNA  level  except 
PC12 cell line. The absence of product in PC12 is due to the fact that the human primers 
used  were  not  complementary  to  the  rat  plexin-B1  DNA  sequence.  There  was  no 
significant  difference  in  plexin-B1  expression  levels  among  all  the  human  cell  lines. 
Sema4D mRNA was also detected in human cells as shown by Figure 3.1. There was a 
rather weak band observed in PC3 cells indicating that the mRNA level of Seam4D in 
PC3 was relatively low compared to the rest of the human cell lines. 92 
 
 
Plexin-B1, 303bp
Sema 4D, 450bp
GAPDH, 597bp
Figure 3.1 mRNA expression levels of plexin-B1 and Sema 4D in cell lines.
RNA was extracted from cells and then subjected to RT-PCR. The PCR products
were then analyzed using agarose electrophoresis. All the human cell lines tested
expressed plexin-B1 mRNA. No plexin-B1 mRNA was detected in PC12 because
the primers were not complementary to rat. Sema4D mRNAwas detected in all the
human cell lines. The Sema4D mRNA expression level in PC3 was relatively low
compared to the rest of the cell lines. GAPDH was amplified as the control.
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3.2.2 Expression of plexin-B1 and Sema4D at the protein level 
To study the expression of plexin-B1 and Sema4D at protein level, a wide range 
of cell lines were investigated. Lysis buffer RIPA (radioimmunoprecipitation) was used 
to extract proteins as it gave least protein degradation compared to other compositions. 
Total lysates of different protein samples were analyzed by Western-blotting following 
SDS-PAGE. As shown in Figure 3.2.A, protein from HEK293 stably transfected with 
plexin-B1 was a positive control for plexin-B1 expression and it exhibited proteins with 
molecular  sizes  of  300 kDa  and  200  kDa.  Compared  with  the  control,  there  was  no 
observable signal of plexin-B1 expression in all the cell lines, even with 80µg of total 
input proteins and over-night exposure. To find out if this missing expression of plexin-
B1 was due to no or low level of target protein, protein samples were then concentrated 
by immunoprecipitation using anti-plexin-B1 antibody and then further analyzed using 
SDS-PAGE and Western-blotting. By using this enrichment step, plexin-B1 expression at 
the size of 300 kDa was detected in prostate cell lines DU145, LNCaP, PC3, 1542CPT 
and 1542NPT (Figure 3.2.B). In human kidney embryonic cells HEK293 and PC12 cells 
which are derived from a pheochromocytoma of the rat, there was no comparable signal 
detected. 
The two pictures in Figure 3.2.C show the Western-blotting results of plexin-B1 
expression using the same Santa Cruz anti-plexin-B1 antibody as Figure 3.2.A and Figure 
3.2.B, but of a different batch number. In all the human epithelial cells from tumors, this 
new batch anti-plexin-B1 antibody recognized endogenous plexin-B1 with lower total 
protein  input  (40µ g)  than  those  in  Figures  3.2.A  and  3.2.B.    Endogenous  plexin-B1 94 
 
protein was present in two forms, a 300 kDa fragment and a predominantly expressed 
smaller fragment at the size of 200 kDa. 
Sema4D expression was detected by Western-blotting using antibody anti-CD100 
(Conrotto et al., 2005). Among the prostate cancer cell lines tested, 22RV1, LNCaP and 
DU145  expressed  Sema4D  with  a  molecular  mass  of  150  kDa.    DU145  was  low  in 
expression of this protein compared with 22RV1 and LNCaP. In the PC3 cell line and the 
PC3-LN3 cell line that is derived from PC3, there was no obvious expression of Sema4D 
(Figure 3.2.B). HEK293 cells and COS7 cells (derived from kidney cells of African green 
monkey) both demonstrated Sema4D protein expression. 95 
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Figure 3.2 Plexin-B1 and Sema4D protein expressions in different cell lines. (A)
Total lysates from different cell lines were analyzed for plexin-B1 protein. None of the
cell line displayed detectable endogenous plexin-B1 protein using the first batch of
anti-plexin-B1 antibody. (B) Cell lysates were enriched by immunoprecipitation with
anti-plexin-B1 antibody (same batch as A). (C) Total lysates were resolved by SDS-
PAGE and probed with anti-plexin-B1 antibody of different batch (batch no..10804).
(D)Proteins from different cell lines were investigated for Sema4D expression through
the Western-blotting method.
Sema4D
C
D
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3.3 Discussion 
As  discussed  in  the  beginning  of  this  chapter,  both  Sema4D  and  its  receptor 
plexin-B1 are reported to be expressed widely in different tissues and organs. Sema4D is 
high  at  mRNA  level  in  skeletal  muscle,  peripheral  blood  lymphocytes,  spleen,  and 
thymus (Hall et al., 1996). In other non-lymphoid organs, including the testes, brain, 
kidney,  small  intestine,  prostate,  heart,  placenta,  lung  and  pancreas,  the  mRNA  of 
Sema4D is expressed at low level (Hall et al., 1996). In this study, I found that mRNA of 
Sema4D was expressed in prostate cancer cell lines except PC3 cells which demonstrated 
rather weak signal compared with the rest. However to assay the mRNA levels more 
accurately, real-time PCR might be more informative and could be applied. At the protein 
level, Sema4D expression was not detectable in PC3 cells consistent with the RT-PCR 
results,  but  was  present  in  other  prostate  cancer  cell  lines  tested.  These  results 
demonstrated that epithelial cells from human prostate cancer are positive for Sema4D 
expression. 
Plexin-B1  is  predominantly  expressed  in  fetal  neural  tissues  (Maestrini  et  al., 
1996). Recently research reported that over-expression of plexin-B1 was associated with 
cancer. In this part of study, I tested a variety of cell lines including human prostate 
cancer cell lines (DU145, PC3, LNCaP, 1542NPT, 1542CPT, 22RV1, PC3-LN3), human 
breast  cancer  cell  line  (MCF7),  human  embryonic  kidney  cell  line  (HEK293)  and 
monkey kidney cell line (COS7). I found that all the cell lines tested were expressing 
detectable amount of pelxin-B1 protein (Figure 3.2). My result have shown, for the first 
time, that plexin-B1 is endogenously expressed in prostate cancer cell lines. Artigiani and 97 
 
her colleagues have demonstrated that plexin-B1 is predominantly found in a cleaved 
form in cells and tissues (Artigiani et al., 2003). The full length receptor plexin-B1 is a 
300 kDa protein which is a single-chain precursor. By proteolytic processing, this protein 
is converted into a heterodimeric receptor consisting of a 200 kDa extracellular moiety 
and a 100 kDa that contains a portion of the transmembrane moiety and the cytoplasmic 
region (Artigiani et al., 2003).  The Western-blotting result by anti-plexin-B1 antibody 
from  Santa  Cruz  showed  that  there  was  a  predominant  expression  of  the  200  kDa 
extracellular domain of plexin-B1 in all the cell lines tested. However, the full length of 
plexin-B1 was low in amount relatively. There was no 100 kDa small fragment of plexin-
B1 detected in all the cell lines studies. The intracellular domain of plexin-B1 consists of 
residues from 1512-2135. The Santa Cruz antibody recognizes amino acids 771-1070 
region  that  locates  in  the  extracellular  domain  of  plexin-B1.  Therefore  this  antibody 
could not bind to the 100kDa fragment of plexin-B1. Interestingly, the batch number of 
this  antibody  also  affected  the  result.  Results  from  different  batches  varied  (Figure 
3.2.A.). However, these results together showed that plexin-B1 was present in prostate 
cancer cell lines. 
Sema4D can act either as membrane-bound or locally released protein to exert its 
regulatory effects. In this study protein plexin-B1 protein is expressed in both DU145 and 
PC3 cell lines. Sema4D protein expression is only observed in cell line DU145 but not in 
PC3. The different expression patterns of the two proteins in these two cell lines suggest 
that the signaling of Sema4D/plexin-B1 in these two cells lines might be different. In 
DU145  cell  line  plexin-B1  could  initiate  downstream  pathways  by  binding  with  the 
autocrine production of Sema4D by DU145 cells. PC3 cells that lack Sema4D protein 98 
 
expression may employ a paracrine signaling method in which plexin-B1 signals through 
Sema4D released by other cells. 
In a summary, the results from this chapter revealed the expression of proteins 
plexin-B1  and  Sema4D  in  prostate  cancer  cell  lines.  It  also  provided  a  relative 
comparison of the protein expression levels between prostate cancer cell lines and other 
human cell lines. 99 
 
 
 
 
Chapter 4 
Plexin-B1 mutation and tyrosine kinases 
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4.1 Introduction 
Phosphorylation at tyrosine residues is thought to be an important way of plexin-
B1 signaling. Plexin-B1 associates in a molecular complex with certain tyrosine kinases. 
Upon  stimulation  by  Sema4D,  both  plexin-B1  and  the  associated  tyrosine  kinase  are 
tyrosine phosphorylated (Giordano et al., 2002; Swiercz et al., 2004). The activation of 
the plexin-B1/RTK (receptor tyrosine kinase) complex results in multiple intracellular 
signaling pathways and subsequently regulation of cell functions. 
Met (also known as c-met) and ErbB-2 are the main receptor tyrosine kinases 
which interact with plexin-B1 and are involved in plexin-B1/Sema4D signaling. Plexin-
B1 binds to Met through their extracellular domains. Binding of Sema4D to plexin-B1 
results in phosphorylation of the tyrosine residues in the cytoplasmic portions of both 
receptors (Conrotto et al., 2004; Giordano et al., 2002). This indirect activation of Met by 
Sema4D promotes Met-mediated invasive growth of cells consequently. 
ErbB-2  associates  with  plexin-B1  into  a  complex  through  their  extracellular 
domains (Swiercz et al., 2004). After ligand Sema4D binds to plexin-B1, the intrinsic 
tyrosine kinase activity of ErbB-2 is stimulated and this results in phosphorylation of 
both plexin-B1 and ErbB-2 (Swiercz et al., 2004). Plexin-B1 forms a complex with PDZ-
RhoGEF/LARG  and  Sema4D/plexin-B1  signaling  regulates  RhoGEF-mediated  RhoA 
activation (Hirotani et al., 2002; Perrot et al., 2002; Swiercz et al., 2002). ErbB-2 is 
critically involved in this signaling process. ErbB-2-mediated phosphorylation of plexin-
B1 is essential for the Sema4D-induced activation of RhoA. 101 
 
Interestingly, ErbB-2 and Met compete for plexin-B1 binding and have opposite 
effects on RhoA activation downstream of Sema4D/plexin-B1 signaling (Swiercz et al., 
2008). Sema4D/plexin-B1 signaling inhibits RhoA activation in cells expressing Met, 
whereas in cell expressing ErbB-2, stimulation of the Sema4D/plexin-B1 pathway results 
in RhoA activation (Swiercz et al., 2008). Figure 4.1 illustrates the reciprocal roles of 
ErbB-2 and Met on plexin-B1 signalling based on Swiercz’s findings.  102 
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Plexin-B1  signaling  pathways  also  involve  non-receptor  tyrosine  kinases 
including the PI3K/Akt and MAPK pathways. In endothelial cells, the Sema4D/plexin-
B1 signaling pathway promotes cell migration through activating phosphatidylinosityl 3-
kinase (PI3K)-Akt (Basile et al., 2005). Plexin-B1 associates with PYK2, the p85 subunit 
of PI3K and to a lesser extent with Src. Activation of plexin-B1 leads to phosphorylation 
of PYK2 which is necessary for consequent Src-dependent activation of the PI3K-Akt 
pathway and for plexin-B1 phosphorylation. The group lead by Dr. Guan has found that 
the MAPK pathway is  activated downstream  of Sema4D/plexin-B1 signaling through 
RhoA activation (Aurandt et al., 2006). Sema4D/plexin-B1 induces Rho activation and 
Rho co-operates with Ras to active Raf, which in turn stimulates ERK (extracellular-
signal-regulated kinase) activation. 
Given  that  tyrosine  kinases  are  important  signalling  partner  molecules  for 
Sema4D/plexin-B1 signal transduction, it is important to know if the mutations have any 
impact on the pathways involving receptor/non-receptor tyrosine kinases. To achieve this, 
exogenous plexin-B1 expression was introduced into cells by transfection with cDNA 
plasmids encoding VSV-tagged plexin-B1 wildtype or mutants A5359G, A5653G and 
T5714C. Cells co-expressing targeted proteins were lysed and immunoprecipitated with 
specific  antibodies  and  then  analyzed  by  Western-blotting  to  study  the  interaction  of 
plexin-B1 wildtype/mutants with ErbB-2 or with Met. Swiercz et al. has demonstrated 
that Sema4D induces or inhibits cell migration depending on the presence of ErbB-2 or 
Met in breast cancer cell lines. However, Conrotto et al. showed the opposite result in 
regulatory effect of Met on cell motility. Conrotto demonstrated that Met activation by 
Sema4D/plexin-B1 signaling promotes cell migration (Conrotto et al., 2005; Giacobini et 104 
 
al., 2008; Giordano et al., 2002). These contradictory results may be due to the different 
cell types investigated. There is no previous report on how prostate cancer cells respond 
to Sema4D. The roles of ErbB-2 and Met on Sema4D/plexin-B1-mediated cell motility in 
prostate cancer cells are not known. In order to reveal the mechanism underlying the 
effect of Sema4D on cell motility in the context of ErbB-2 and Met expression in prostate 
cancer cells, I investigated the expressions of ErbB-2 and Met in prostate cancer cell lines 
and carried out cell migration assays with these cells. To study if the Akt and MAPK 
pathways are involved in Sema4D/plexin-B1 signaling in epithelial cells, I used HEK293 
cells  expressing  exogenous  plexin-B1  and  studied  the  phosphorylation  levels  of  the 
tyrosine kinases under the effect of Sema4D treatment. 105 
 
4.2 Results 
4.2.1 Interaction between plexin-B1 and ErbB-2 
The HEK293 cell line was used for protein-protein interaction studies throughout 
my project. Before using HEK293 cells, prostate cancer cell lines DU145 and PC3 were 
transfected with  exogenous  plexin-B1 with the  purpose of  performing  protein-protein 
interaction assays. However, I did not successfully establish prostate cancer cell lines 
expressing exogenous proteins because the transfection efficiency for DU145 and PC3 
was very low. Therefore, I used HEK293 cells that are easy to work with and transfect. 
HEK293 cells were seeded in 6-well plates and each well was transfected with 4 µg of 
plasmids  in  total.  The DNA components  of each sample in  Figure 4.2.A is  listed as 
followed, 
  Plexin-B1 plasmid (µ g)  ErbB-2 plasmid (µ g)  PDZ-RhoGEF plasmid (µ g) 
Lane 1  1 (pcDNA3)  1.5  1.5 
Lane 2  2  -  2 
Lane 3  1  1.5  1.5 
Lane 4  2  2  - 
Lane 5  1.33  1.33  1.33 
Lane 6  2  1  1 
 
The first panel of Figure 4.2.A shows the interaction of plexin-B1 with ErbB-2 by 
immunoprecipitation. Lane 1 was set as the control which was transfected with an empty 
vector instead of plexin-B1. The pull-down assay was performed with anti-VSV antibody 106 
 
and the Western-blotting was performed with anti-ErbB2 antibody. It is expected to see 
no signal in Lane 1, since the empty vector is not VSV-tagged. No signal of interaction 
between  plexin-B1  and  ErbB-2  is  observed  as  expected.  This  indicates  that  the 
immunoprecipitation is specific for VSV-tagged plexin-B1 protein or a protein complex 
containing VSV-plexin-B1. Lane 2 represents cells co-expressing VSV-plexin-B1 and 
PDZ-RhoGEF proteins and the weak band indicates the binding between VSV-plexin-B1 
and endogenous ErbB-2. Lanes 3, 5 and 6 demonstrate the interaction between exogenous 
VSV-plexin-B1 and ErbB-2 at different ratios of transfected plasmids. Compared with 
the signal from lane 2, the binding signals in those lanes are much stronger, resulting 
from  a  relatively  high  level  of  exogenous  ErbB-2  protein  expression.  Lane  4  is  the 
protein  immunoprecipitated  from  cells  co-expressing  plexin-B1  and  ErbB-2  in  the 
absence of PDZ-RhoGEF. Interaction between plexin-B1 and ErbB-2 is still observed 
and this indicates that PDZ-RhoGEF is not necessary for plexin-B1/ErbB-2 interaction. 
Lane 4 gives the strongest signal of plexin-B1/ErbB-2 binding. This is due to the higher 
DNA input at transfection, resulting in a relatively higher proportion of plexin-B1 and 
ErbB-2 in total lysates than those of the rest of the samples. The lower panels of Figure 
4.2.A shows the expressions of exogenous proteins, indicating the input of protein for 
immunoprecipitation is equal among different lanes. 
Figure 4.2.B is the mirror experiment of immunoprecipitation. Proteins from cells 
co-expressing plexin-B1 and ErbB-2 were extracted and immunoprecipitated with anti-
ErbB-2.  The  Western-blotting  result  confirms  the  interaction  between  plexin-B1  and 
ErbB-2, as demonstrated by the left panel of the figure. The same membrane was stripped 
of  antibodies  and  re-probed  with  anti-ErbB-2  antibody.  The  right  panel  shows  the 107 
 
expression of ErbB-2 in the cell lysate used in the immunoprecipitation, showing the 
level of ErbB2 input protein. 
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Figure 4.2 Interaction between plexin-B1 and ErbB-2. HEK293 cells were co-
transfected with different ratios of plasmid DNA encoding plexin-B1, PDZ-
RhoGEF and ErbB-2 as indicated. Proteins were extracted with RIPA buffer and
samples were immunoprecipitated with antibodies. (A) Cell lysates were
immunoprecipitated with anti-VSV antibody and then probed with anti-ErbB-2 in
Western-blotting. Different lanes of blots represent protein from cells transfected
with different ratio of plasmid DNA (as shown in table above). (B) The mirror
experiment of immunoprecipitation was performed using anti-ErbB-2 antibody
and followed by anti-VSV antibody incubation in Western-blotting.
1 2 3 4 5 6
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4.2.2 Interaction between ErbB-2 and mutated forms of plexin-B1 
With the association of ErbB-2 and plexin-B1 confirmed, I then studied if the 
mutated forms of plexin-B1 had any effects on its binding to ErbB-2. Constructs of DNA 
expressing VSV-tagged plexin-B1 wildtype and mutated forms were from previous group 
member  Oscar  Wong  and  are  described  in  his  thesis.  HEK293  were  transiently  co-
transfected with wildtype/mutant plexin-B1 and ErbB-2. The upper blot in Figure 4.3 
shows that plexin-B1 wildtype, mutants A5359G, A56553G, T5714C and C5060T all 
demonstrate binding to ErbB-2. There is no alteration in the interaction between plexin-
B1and ErbB-2 in any mutated form of plexin-B1 compared with the wildtype plexin-B1. 
The lower blot shows that the protein input for all samples is equal. 110 
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Figure 4.3 Effect of plexin-B1 mutations on ErbB-2 and plexin-B1
interaction. HEK293 cells were transiently transfected with plasmid DNA
encoding ErbB-2 and plexin-B1 wildtye or mutated forms (VSV tagged).
Lysates were cleared and immunprecipiated with anti-VSV antibody. Samples
were then analyzed by SDS-PAGE followed by Western-blotting with primary
antibody anti-ErbB-2. All the mutated forms of plexin-B1 bind to ErbB-2 to the
same extent as the wildtype does.
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4.2.3 Interaction between plexin-B1 and Met 
In  order  to  study  the  binding  of  plexin-B1  and  Met,  HEK293  cells  were 
transfected  with  plasmids  encoding  VSV-tagged  plexin-B1  wildtype/mutants  and  full 
length Met. Cells were plated in 6-well plates and each well was transfected with 4 µg of 
DNA in total. The DNA composition of the samples in lanes in Figure 4.3 is listed below, 
  Plexin-B1 plasmid (µ g)  Met plasmid (µg) 
Lane 1  2  2 
Lane 2  3  1 
Lane 3  1  3 
Lane 4  2  - 
Lane 5  -  2 
 
The precursor of Met is a single-chain protein of 170 kDa. The precursor protein 
is glycosylated and then cleaved into an extracellular 50 kDa α-chain and a 145 kDa β-
chain consisting of a large extracellular domain, the transmembrane segment and the 
intracellular tyrosine kinase region (Giordano et al., 1989; Mondino et al., 1991). The 
anti-Met antibody used in this study is to recognize the cytoplasmic domain of Met, i.e., 
the  170  kDa  and  145  kDa  forms.  The  Lane  4  of  panel  2  in  Figure  4.4  shows  the 
expression of endogenous Met. The antibody recognizes the 145 kDa fragment of Met. In 
addition to the expression of 145 kDa form of Met, cells transfected with the Met plasmid 
express the Met precursor with a molecular mass of 170 kDa. Cell lysates were then 
immunoprecipitated  with  anti-VSV  antibody  to  investigate  the  interaction  between 
plexin-B1 and Met. In control sets, cells were either transfected with plexin-B1 alone 112 
 
(lane 4) or Met alone (lane 5) respectively. There is no sign of pull-down of Met with 
anti-VSV antibody in lanes 4 and 5 showing that the bands in the other lanes (from cells 
transfected with both plasmids) are specific for Met and VSV-plexin-B1 binding. In cells 
introduced with exogenous expression of plexin-B1 and Met (lanes 1, 2 and 3), 170 kDa 
Met is immunoprecipitated indicating the interaction between plexin-B1 and Met. There 
is no sign of interaction between plexin-B1 and the 145 kDa Met in the first two lanes 
(lanes  1  and  2),  whereas  in  cells  expressing  relative  high  Met  (3  µg  DNA,  lane  3) 
immunoprecipitation result shows 145 kDa Met also interacts with plexin-B1. Cell lysate 
from Lane 3 contained higher proportion of Met in total protein than Lanes 1 and 2. 
These results suggest that plexin-B1 couples with 170 kDa Met. However, the 145 kDa 
Met binds to plexin-B1 to a lesser extent in comparison with precursor form of Met. 
Interaction between plexin-B1 and the 145 kDa fragment of Met is observed only in the 
case of high over-expression of Met, indicating that plexin-B1 binds predominantly to the 
N-terminal extracellular region of Met and more weakly with 145 kDa fragment. 113 
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Figure 4.4 Interaction between plexin-B1 and Met. HEK293 cells were
transiently transfected with different ratio of Met and VSV-plexin-B1 plasmid
DNA (shown in table above). Proteins were extracted and immunoprecipitated
with anti-VSV antibody and then analyzed by Western-blotting.
1 5 3 4 2
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4.2.4 Interaction between Met and mutated forms of plexin-B1 
To study the effect of plexin-B1 mutations on plexin-B1 binding to Met, I co-
transfected  HEK293  cells  with  VSV-tagged  plexin-B1  wildtype/mutants  and  Met 
plasmids. Cells were plated in 6-well-plates and each well was co-transfected with 2 µg 
of Met and 2 µg of plexin-B1 or vector control. The Western-blotting result of total lysate 
shows  that  when  co-expressed  with  plexin-B1,  the  expression  of  Met  (170  kDa)  is 
suppressed  compared  with  the  vector  control  (Figure  4.5,  3
rd  panel).  In 
immunoprecipitation assays, 170 kDa Met was found to be co-precipitated with all the 
mutated forms of plexin-B1 (A5359G, A56553G, T5714C) and wildtype plexin-B1 by 
anti-VSV antibody as shown in Figure 4.4. There is no interaction of 145 kDa Met and 
plexin-B1 detected. This suggests that mutated forms of plexin-B1 interact with Met at 
the same extent as wildtype plexin-B1 to Met. Mutations of plexin-B1 have no effect on 
its binding to Met. 115 
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Figure 4.5 Effect of plexin-B1 mutations on Met and plexin-B1 interaction.
HEK293 cells were transiently transfected with plasmid DNA encoding Met
and plexin-B1 wildtye or mutated forms (VSV tagged). Lysates were cleared
and immunprecipiated with anti-VSV antibody. Samples were then resolved by
SDS-PAGE and analyzed by Western-blotting with primary antibody anti-Met.
All the mutations bind to Met (170kDa) to the same extent as wildtype plexin-
B1 does.
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4.2.5 Effect of ErbB-2 and Met expression on cell migration in prostate cancer cells 
As  mentioned  in  the  introduction  to  this  section,  the  response  of  cells  to 
Sema4D/plexin-B1 signaling is cell specific and is dependent on the ratio of Met and 
ErbB-2 expression in the responding cells (reviewed in 4.1 of Chapter 4). To study the 
regulatory  functions  of  these  two  tyrosine  kinases  in  prostate  cancer  cells,  I  firstly 
screened prostate cancer cells for expression levels of ErbB-2 and Met. As shown in 
Figure  4.6.A,  several  human  epithelial  cell  lines  and  monkey  cells  COS7  were 
investigated for the expression of ErbB-2 and Met. Of all the cell lines tested, prostate 
cancer cell lines PC3 and PC3-LN3 exhibit much stronger expression of Met compared to 
the rest. LNCaP cells show null expression of Met. MCF7 is not expressing Met which is 
consistent with a previous report (Swiercz et al., 2008). In comparison, PC3 and LNCaP 
cells demonstrate different patterns of ErbB-2 expression (Figure 4.6.A). LNCaP cell line 
is strongly expressing ErbB-2, whereas ErbB-2 is expressed at relatively low levels in 
PC3 cells. These results demonstrate that the stoichiometry of Met and ErbB-2 in LNCaP 
and PC3 cells is different from each other. Based on this finding,  I then studied the 
motility of these cells. 
Previously, my supervisor Dr. Magali Williamson has demonstrated that Sema4D 
treatment increases the motility of LNCaP cells compared with the control untreated cells 
(Figure 4.6.S). In this section, I performed transwell migration assays with PC3 cells. 
Cells were treated with or without Sema4D concentrate. Sema4D was added to the lower 
wells  of the transwell chamber.  The  cell seeding efficiency  for each experiment  was 
different, resulting in a great variance of starting cell numbers between trials. Therefore 117 
 
the number of cells migrated through with Sema4D treatment was normalized to that of 
the migrated cells in the control. The relative cell migration was calculated. I found that 
Sema4D treatment decreases the cell motility in PC3 cells (Figure 4.6.B). These results 
suggest that in prostate cancer cells Sema4D induces cell migration in the presence of 
ErbB-2, whereas Sema4D inhibits cell migration when Met expression is dominant. This 
finding is consistent with the results observed in breast cancer cells reported by Swiercz 
(Swiercz et al., 2008). 118 
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Figure 4.6 Effect of Sema4D on PC3 cell motility. (A) Expression levels of
Met and ErbB-2 in different cells detected by Western-blotting. (B) PC3 cells
were plated in the transwell inserts which were coated with fibronectin on the
lower side. Cells were incubated for 8 hours with or without Sema4D. At the
end of incubation, cells on the lower side of the inserts were fixed and stained
with crystal violet. Relative migration ability was measured as cells migrated
normalized to that in the control (The raw data is presented in Appendix 3).
The experiment was repeated at least three times and SEM was indicated as the
error bar.
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Figure 4.6S. Sema4D increases the motility of LNCaP cells. Transwell
migration assays were performed using 24-well, 0.8 mm transwell
chambers (BD) with LNCaP cells (2 x104 per insert) in the upper
chamber incubated with RPMI +/- Sema4D (100 ng/ml) in lower
chamber. After 6hrs, cells on underside were fixed, stained with crystal
violet and counted. Assays performed 4 times in triplicate. Error bars
represent SEM, (p=0.002, 2 tailed T-test). (from Dr. Magali Williamson)
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4.2.6 Plexin-B1 and Akt/MAPK pathways in epithelial cells 
To  study  the  downstream  pathways  involved  in  Sema4D/plexin-B1  signaling, 
recombinant  Sema4D-Fc  was  produced.  Sema4D-Fc  was  generated  and  purified  as 
described in Chapter 2. Sema4D-Fc concentrate was then resolved by SDS-PAGE and 
stained with coomassie blue. Serial dilutions of BSA were loaded as the standards for 
protein amount. Sema3A-Fc (R&D) was loaded as a semaphorin protein control. Figure 
4.7.A shows the yield of Sema4D-Fc. Sema4D-Fc demonstrates two fragments at the 
sizes of around 150 kDa and 120 kDa. The concentrate of Sema4D-Fc could be estimated 
by comparing the band to those of BSA standards. 
HEK293 cells were transfected with plexin-B1 plasmid or control vector for 48 
hours. Cells were serum starved overnight and incubated with Sema4D (200 ng/ml) for 
15 minutes. LPA (200 ng/ml) treatment was applied as the positive control for MAPK 
activation (Ediger et al., 2003). Proteins were then extracted and proteins involved in 
PI3K/Akt or MAPK pathways were analyzed for their phosphorylation levels. HEK293 is 
null in PYK2 expression as shown in the Western-blotting of Figure 4.7.B. There is a 
basic level of phosphorylated Akt in HEK293 cells. No alteration in expression level of 
the phosphorylated form of Akt is observed in samples incubated with Sema4D. However 
MEK1/2, which is part of MAPK signaling pathway, is activated. Like LPA, Sema4D 
increases the expression of phosphorylated MEK1/2 both in cells transfected with plexin-
B1  or  vector  control.  This  suggests  that  endogenous  plexin-B1  in  HEK293  cells  are 
responsible  for  Sema4D-induced  MEK1/2  phosphorylation.  The  phosphor-MEK1/2  in 
cells  transfected  with  plexin-B1  is  slightly  higher  than  the  vector-transfected  cells, 121 
 
suggesting that over-expression of plexin-B1 makes cells respond to Sema4D at higher 
magnitude. These preliminary results  suggest  that  Sema4D may have  some effect  on 
MAPK pathway activation in epithelial cells. 
I  then  treated  cells  either  with  increasing  concentrations  of  Sema4D  or  with 
increasing incubation times with Sema4D to further study the MAPK pathway. In cells 
transfected  with  plexin-B1,  Sema4D  induces  MEK1/2  phosphorylation  at  the 
concentration 100 ng/ml and with increasing concentrations the MEK1/2 phosphorylation 
level stays elevated (Figure 4.7.C). However, there is a drop at the dose of 800 ng/ml. In 
the  time-dependent  study,  phosphorylation  level  of  MEK1/2  induced  by  Sema4D 
increases at time point 5 minutes and is slightly higher at time point 10 minutes. The 
elevated level of phosphorylated MEK1/2 is still observed at 30 minutes. Erk1/2, which 
is downstream of MEK1/2, is also activated by Sema4D as shown in Figure 4.6.D. The 
increased level of Erk1/2 appears at time point 5 and peaks at time point 10. After 30 
minutes incubation, there is an obvious drop of phospho-Erk1/2 compared with earlier 
time  points.  These  results  show  that  Sema4D  promotes  MAPK  pathway  proteins 
activation in epithelial cells. 
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Figure 4.7 Akt and MAPK pathways under the effect of Sema4D. (A) Purified
Sema4D was generated as described in Chapter 2. 15 µl of Sema4D concentrate was
analyzed by SDS-PAGE and coomassie blue staining. The amount of Sema4D
protein loaded could be estimated according to the staining of BSA standard.
Approximate concentration of Sema4D could be calculated. (B) HEK293 transfected
with VSV-tagged plexin-B1 or empty vector was serum starved overnight and then
incubated with LPA (200 ng/ml) or Sema4D (200 ng/ml) for 15 minutes. Lysates
were analyzed forAkt and MAPK pathway proteins using specific antibodies.123 
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Figure 4.7 Akt and MAPK pathways under the effect of Sema4D. (C) HEK293
cells expressing exogenous plexin-B1 were treated with Sema4D with different
concentrations for 15 minutes and analyzed for MEK activation status. (D) HEK293
cells transfected with exogenous plexin-B1 were incubated with Sema4D (200
ng/ml) with increasing time intervals. Cells transfected with empty vector were set as
the control. Proteins of interest were then examined by Western-blotting.
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In the experiments in the previous sections, glycine (neutralized with Tris) was 
used as the vehicle for Sema4D delivery. To further confirm the MAPK activation, cells 
treated with vehicle control glycine (neutralized by Tris) were used as a proper control. 
HEK293  cells  transfected  with  plexin-B1  or  vector  control  were  either  treated  with 
Sema4D concentrate or with neutralized glycine (of the same volume as Sema4D) with 
different incubation time intervals. Both glycine and Sema4D concentrate induces MAPK 
activation (MEK1/2 and Erk1/2 phosphorylation) as shown in Figure 4.8.A. To eliminate 
the  effect  of  glycine  on  MAPK  activation,  Sema4D-AP  eluted  with  glutathione  was 
applied to the cells and glutathione was set as the vehicle control. Figure 4.8.B illustrates 
the Sema4D-AP protein by Coomassie blue staining following SDS-PAGE. Glutathione 
alone induces MAPK activation as glycine does (Figure 4.8.C). These results suggest that 
both glycine and glutathione have positive effect on MAPK activation and this effect may 
mask the effect of Sema4D. Therefore, I performed dialysis with the eluted Sema4D 
concentrate using PBS as the dialysis buffer. The same experiment was carried out and 
cells were incubated with either PBS or PBS-dialyzed Sema4D. Again PBS exhibits a 
positive effect on promoting activation of MAPK, the same as glycine and glutathione 
(Figure 4.8.D). Conditioned medium containing Sema4D was used instead of purified 
Sema4D. Cells were either incubated with Sema4D-containing medium or medium from 
cells transfected with vector only (MOCK). Figure 4.8.E shows that cells demonstrate 
increased phosphorylation level of MAPK in both MOCK and conditioned medium. 125 
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Figure 4.8 Effect of Sema4D in different solvents on MAPK activation. (A)
HEK293 transfected with VSV-tagged plexin-B1 or empty vector was serum starved
overnight and then incubated with Sema4D (200 ng/ml) or glycine (the same volume as
Sema4D) for different time intervals. Lysates were analyzed for Akt and MAPK
pathway proteins using specific antibodies. (B) Purified Sema4D-AP was generated as
described in Chapter 2. 15 µl of Sema4D concentrate was analyzed by SDS-PAGE and
coomassie blue staining. The amount of Sema4D protein loaded could be estimated
according to the staining of BSA standards. Approximate concentration of Sema4D
could be calculated. (C) HEK293 cells expressing plexin-B1 or carrying empty vector
were incubated with Sema4D-AP (200 ng/ml) or glutathione with different time
intervals and analyzed for MAPK activation.
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Figure 4.8 Effect of Sema4D in different solvents on MAPK activation. (D)
HEK293 cells expressing exogenous plexin-B1 were incubated with dialyzed Sema4D
(200 ng/ml) or PBS for different time intervals. Cells with empty vector were set as the
control. Proteins of interest were the examined by Western-blotting. (E) Conditioned
medium containing Sema4D was generated as described in Chapter 2. Cells were serum
starved overnight and incubated with conditioned medium or medium from cells
transfected with empty vector. MAPK pathway proteins were analyzed by Western-
blotting.
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4.2.7 Plexin-B1 mutations and MAPK pathway   
In order to study if mutations of plexin-B1 have any impact on Sema4D-induced 
activation of Akt pathway proteins, HEK293 cells were over-expressed with plexin-B1 
wildtype or mutants. As shown in Figure 4.9, Sema4D induces MEK1/2 activation in 
cells expressing plexin-B1 wildtype. In cells expressing mutated forms of the protein, the 
magnitude of elevation of phospho-MEK1/2 induced by Sema4D is not different from the 
wildtype.  Although,  as  suggested  in  the  previous  section,  the  effect  of  Sema4D  on 
MEK1/2 phosphorylation is masked by the effect of the vehicle solution, the finding in 
this  section  suggests  that  the  mutated  forms  of  plexin-B1  have  no  impact  on  the 
Sema4D/plexin-B1 induced MAPK activation or the alteration by mutation could not 
overcome the masking effect of other factors. 
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Figure 4.9 MAPK activation in cells expressing plexin-B1
wildtype/mutants. HEK293 cells were transfected with plexin-B1
wildtype/mutants. On the second day of transfection, cells were serum starved
overnight and then incubated with Sema4D (200 ng/ml) for 15 minutes. Cells
were harvested and proteins were extracted. The protein of interest was the
examined by Western-blotting.
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4.3 Discussion 
4.3.1 Plexin-B1 mutations and receptor tyrosine kinases 
Met belongs to the scatter factor receptor family. Met, plexin-B1 and Sema4D all 
share homology in their extracellular domain, and contain a conserved sequence of ~500 
amino  acids  called  the  Sema  domain  (Maestrini  et  al.,  1996).  Met  elicits  a  complex 
sequence of events resulting in invasive growth in cells upon HGF binding. ErbB-2 is 
notable for its role in breast cancer progression and over-expression of ErbB-2 is also 
found in ovarian cancer, stomach cancer in addition to breast cancer. There is no ligand 
known for ErbB-2 and it can only be activated by dimerization with other members of 
ErbB family (Olayioye et al., 2000). Both Met and ErbB-2 have recently been implicated 
in  Sema4D/plexin-B1  signaling  by  coupling  with  plexin-B1.  In  the  first  part  of  this 
chapter, interaction between the receptor tyrosine kinases Met/ErbB-2 and plexin-B1 was 
studied. Using immunoprecipitation, I confirmed that plexin-B1 interacts with ErbB-2 
and Met. Plexin-B1 binds to either ErbB-2 or Met through their extracellular domains 
(Swiercz et al., 2004). The mutated forms of plexin-B1, A5359G, A5653G and T5714C, 
are all site mutated in the cytoplasmic domain. There is no alteration of plexin-B1/ErbB-2 
or plexin-B1/Met binding in all the mutated forms of plexin-B1. These results suggest 
that mutations of plexin-B1 located in the cytoplasmic domain do not have any effect on 
its extracellular portions and do not induce any changes of its binding ability to these two 
receptor tyrosine kinases. 
Different  groups  have  reported  that  plexin-B1  interacts  with  receptor  tyrosine 
kinases and both Met and ErbB-2 are involved in the Sema4D/plexin-B1 regulated cell 130 
 
function. However, there are controversial findings about the cell responses regulated by 
RTK/plexin-B1 signaling. The Italian group has shown that Sema4D induces invasive 
growth by coupling with Met via plexin-B1 (Conrotto et al., 2004; Conrotto et al., 2005; 
Giordano et al., 2002). By applying scatter assays, transwell motility assays, soft agar 
growth  assays  and  3-D  growth  assays  in  collagen  type  I,  they  observed  consistent 
increased  cell  metastatic  behavior  in  mouse  epithelial  liver  cells  MLP29,  human 
endothelial cells HUVECs and mouse fibroblast cells NIH 3T3 (Conrotto et al., 2004; 
Giacobini  et  al.,  2008;  Giordano  et  al.,  2002).  The  German  group  also  reported  the 
involvement of Met in Sema4D/plexin-B1 signaling (Swiercz et al., 2008). In cell models 
established in breast cancer cells, they found ErbB-2 and Met have opposite effects on 
cell motility after Sema4D activation. Sema4D promotes cell motility through activation 
of  RhoA  which  is  dependent  on  ErbB-2.  Whereas,  Sema4D  inhibits  cell  migration 
through inactivation of RhoA via Met. Combining results from these two groups, the role 
of  Met  in  regulation  of  cell  movement  through  Sema4D/plexin-B1  signaling  is 
contradictory.  ErbB-2  and  Met  compete  for  plexin-B1  (Swiercz  et  al.,  2008).  The 
controversial  role  of  Met  in  cell  motility  regulation  might  be  determined  by  the 
stoichiometry of ErbB-2, Met and plexin-B1 expression in each cell type. This is also 
consistent with the dual role of Sema4D as an attractive or repulsive cue in regulating cell 
movement.  Based  on  these  findings,  I  investigated  the  role  of  Met  and  ErbB-2  in 
Sema4D-induced cell migration in prostate cancer cells. LNCaP cells express ErbB-2 but 
are null in Met expression. In comparison, PC3 cells express Met and exhibits relatively 
low level of ErbB-2 expression. Previously, our group has demonstrated that Sema4D 
increased cell migration ability in LNCaP cells using transwell migration assays. In this 131 
 
study, it is shown that Sema4D inhibits PC3 cells from migrating through the membrane 
of transwells. Taken together, these findings are the first to suggest the reciprocal roles of 
ErbB-2 and Met on cell motility via plexin-B1 within prostate cancer cells. In LNCaP 
cells  Sema4D  increases  cell  motility  in  the  presence  of  ErbB-2  expression.  In  PC3, 
Sema4D decreases cell motility suggesting that Met has overcome the effect of ErbB-2 
and exhibits an inhibitory effect on cell motility. These results are consistent with the 
theory of opposite roles of ErbB-2 and Met on cell motility via plexin-B1 by Swiercz 
group. 
Due to time limitation, further study was not carried on. siRNA targeting Met 
could  be  applied  in  prostate  cancer  cell  line  PC3  to  study  if  the  Sema4D-induced 
suppression of cell motility could be abolished. In the same way siRNA against ErbB-2 
could be infected into LNCaP cells and meanwhile Met could be introduced to LNCaP 
cells. Migration assays could be carried out in these cells to investigate if the Sema4D-
induced increase of cell motility is suppressed. To further confirm the regulatory role of 
Met/ErbB-2  on  Sema4D/plexin-B1  induced  RhoA  inactivation/activation  in  prostate 
cancer  cells,  RhoA  inactivation/activation  in  response  to  Sema4D  in  both  PC3  and 
LNCaP cells could also be examined. 
 
4.3.2 Plexin-B1 mutations and the Akt/MAPK pathways 
  In endothelial cells, Sema4D induces activation of the PI3K-Akt pathway. In this 
study,  I  aimed  to  study  if  Sema4D/plexin-B1  signaling  had  any  effect  on  PI3K-Akt 132 
 
pathway in epithelial cells. There is no Sema4D-induced activation of Akt in epithelial 
cells,  suggesting  that  Sema4D-induced  activation  of  PI3K-Akt  pathway  might  be 
restricted to endothelial cells. MAPK activation is observed in growth cone in response to 
axon guidance molecules (Campbell and Holt, 2003; Pasterkamp et al., 2003). Sema4D 
acts as axon guidance cue and could also activate MAPK pathway. In epithelial cells I 
found that Sema4D also activates MEK1/2 and Erk1/2.  However, control  experiment 
shows  that  the  effect  of  Sema4D  on  MAPK  has  been  masked  by  Sema4D  carrying 
vehicles  such as  glycine and glutathione. There has  been reported that glycine could 
indirectly induced MAPK activation (Campbell and Holt, 2003). To avoid the masking 
effect  of  Sema4D  by  other  factors,  I  dialyzed  Sema4D  concentrate  to  get  rid  of  the 
vehicle  molecules.  Surprisingly  MAPK  activation  is  still  observed  in  PBS  control 
samples. MAPK activation is induced by many factors and it is directly downstream of 
Sema4D/plexin-B1  signaling.  Therefore  the  effect  of  Sema4D  on  MAPK  could  be 
affected by many factors. As shown in this chapter, the interfering factors could not be 
completely  subtracted.  I  also  investigated  the  MAPK  response  to  Sema4D  in  cells 
expressing  mutated  forms  of  plexin-B1.  I  did  not  observe  any  alteration  in  MAPK 
activation  between  the  mutants  and  wildtype  in  response  to  Sema4D  treatment.  If 
mutated  forms  of  plexin-B1  had  lower  capacity  in  activating  MAPK,  the  effect  of 
interfering factors on MAPK activation could be strong enough to cover the alteration. If 
the mutated forms had increased ability to stimulated MAPK, it is also possible this effect 
could  not  be  observed  because  the  interfering  factors  have  made  the  phosphorylated 
forms of MEK1/2 or Erk1/2 saturated. A conclusion could not be drawn as to whether 
mutated forms of plexin-B1 have any effect on MAPK activation. 133 
 
 
 
 
Chapter 5 
Mutation of plexin-B1 and cell migration 
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5.1 Introduction 
  Three of the mutated forms of plexin-B1 investigated in this thesis were found in 
the metastases of clinical prostate cancer tissues (mutant A5653G, T5714C) or prostate 
cancer  cell  lines  (A5359G,  only  in  LNCaP  cells),  also  the  frequency  of  plexin-B1 
mutations were higher in metastases than primary tumors (Wong et al., 2007). Previously 
our group members Dr. Oscar Wong and Dr. Tharani Nitkunan have demonstrated that 
mutated  forms  of  plexin-B1  have  changed  cell  phenotypes  using  cell  spreading,  cell 
invasion, and cell collapse assays. These results suggest that the mutated forms of plexin-
B1 results  in  increased  metastatic abilities.  In this  chapter,  I  carried out  experiments 
aiming  to  find  out  if  mutated  forms  of  plexin-B1  have  any  effect  on  cell  motility. 
HEK293  cells  stably  over-expressing  plexin-B1  wildtype/mutants  were  subjected  to 
migration assays using a transwell system. 
 
5.2 Results 
  Pools  of  HEK293  cells  stably  expressing  plexin-B1  wildtype/mutants  were 
obtained from Dr. Magali Williamson. Firstly I performed Western-blotting to confirm 
the  plexin-B1  protein  expression.  Figure  5.1.A  shows  that  all  the  transfectant  pools 
express plexin-B1 protein at 300 kDa. These cells were then applied to migration assays. 
The graph in  Figure 5.1.B shows  that cells  expressing  wildtype plexin-B1 has  lower 
motility  relative  to  vector  control,  suggesting  that  wildtype  plexin-B1  may  have  an 
inhibitory  effect  on  motility.  The  motility  of  cells  expressing  mutants  A5359G  and 135 
 
A5653G  is  significantly  higher  relative  to  both  wildtype  and  vector  control  cells, 
indicating a gain of function. Mutant T5714C shows higher motility than the wildtype at 
a less threshold compared with the other mutants and the same motility as the vector 
control, suggesting a loss of inhibitory function of wildtype plexin-B1. Sema4D did not 
initiate statistically significant change of motility compared to untreated cells. 
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Figure 5.1 The motility of cells expressing plexin-B1 wildtype/mutants.
(A) HEK293 cells were stably expressing plexin-B1 wildtype/mutants.
Cells were lysed and proteins were resolved by SDS-PAGE. Western-
blotting result was performed by using anti-plexin-B1 antibody as the
primary antibody. (B) Cells expressing plexin-B1 wildtype/mutants were
applied to transwells for migration assays. Cells were treated with or
without Sema4D (400 ng/ml). The bottom cells were fixed and stained at
the end of migration assay. The relative migration of cells were calculated
as the cells migrated relative to vector control (The raw data is presented
in Appendix 3). All the experiments were repeated at least three times and
the error bars stand for the standard error of the mean.
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5.3 Discussion 
  Plexin-B1 has  been implicated in  the regulation of a variety of cell functions 
including cell migration, axon guidance and neurite outgrowth. The ultimate aim of this 
project is to find out how the mutations affect cell signalling and cell functions. By using 
migration  assays  I  found  that  cells  expressing  mutated  forms  of  plexin-B1  exhibit 
increased motility relative to cells expressing wildtype plexin-B1. This result is consistent 
with the time-lapse experiment of Dr. Tharani Nitkunan (Wong et al., 2007). She did the 
assays  without  Sema4D,  therefore  the  effect  could  be  autocirne  Sema4D/plexin-B1 
signalling for her experiment. In this study, I looked at the effect of externally applied 
Sema4D.  However,  I  did  not  observe  the  difference  between  untreated  and  Sema4D 
treated  cells.  It  has  been  suggested  that  over-expression  of  plexin-B1  results  in 
constitutively  active  plexin-B1  (Conrotto  et  al.,  2004).  Over-expressed  plexin-B1 
wildtype/mutants  in  HEK293  cells  could  be  constitutively  active  and  mediate  cell 
motility independent of Sema4D. Also HEK293 cells express Sema4D (Figure 3.2). The 
increase in motility resulting from mutations of plexin-B1 could be due to a number of 
factors. The loss of R-Ras GAP activity and the loss of inhibition on Rac activity for 
mutants will both result in an increase in cell motility. Met and ErbB-2 also regulate cell 
motility.  The  increased  motility  of  plexin-B1  mutants  is  probably  due  to  a  balance 
between all these factors. My group member Dr. Magali Williamson and Dr. Oscar Wong 
have  also  found  that  mutated  forms  of  plexin-B1  expressing  cells  demonstrate  other 
metastatic phenotypes. All the three mutated forms of plexin-B1, A5359G, A5653G and 
T5714C confer an increased capacity to spread and invade. This evidence supports the 138 
 
hypothesis  that  mutation  of  plexin-B1  promotes  the  progression  of  cells  to  more 
metastatic and malignant state. 
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Chapter 6 
Plexin-B1 mutation and RhoD GTPase 
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6.1 Introduction 
  The Rho subfamily of small GTPases including Rac and Cdc42 are important 
regulators for actin reorganization. Recently small Rho GTPases have been shown to be 
highly involved in plexin-B1 signaling transduction. Plexin-B1 signaling mediated by 
several  Rho  GTPases,  regulates  many  actin-driven  processes  such  as  growth  cone 
collapse, axon guidance and cell migration.  Activation  of Rac results in lamellipodia 
formation. GTP-bound Rac binds to a CRIB-like motif in the non-conserved region of the 
cytoplasmic domain of plexin-B1 (Tong et al., 2007). In this way plexin-B1 sequesters 
Rac1 from its downstream effector PAK and inhibits actin polymerization (Vikis et al., 
2002). Rho mediates the formation of stress fibers. Rho switches from inactive GDP-
bound  form  into the  active  GTP-bound  state  by  guanine  nucleotide  exchange  factors 
(GEFs), including PDZ-RhoGEF, leukemia-associated RhoGEF (LARG) (Boguski and 
McCormick, 1993). Plexin-B members possess a PDZ-binding motif in their carboxyl 
terminal through which plexin-B1 binds to the PDZ domain of PDZ-RhoGEF/LARG, 
resulting in Rho activation and subsequent neurite retraction and growth cone collapse in 
response to Sema4D (Hirotani et al., 2002; Perrot et al., 2002; Swiercz et al., 2002). Rnd1, 
a member of Rho family, is critically involved in this plexin-B1-mediated Rho activation 
in  COS7  cells.  Rnd1  binds  to  cytoplasmic  domain  of  plexin-B1  and  this  interaction 
enhances  the  interaction  between  PDZ-RhoGEF  and  plexin-B1,  potentiating  PDZ-
RhoGEF-mediated RhoA activation (Oinuma et al., 2003). 
  The  research  group  led  by  Dr.  M.  Buck  demonstrates  consistent  result  of 
interaction between plexin-B1 and small GTPases proteins using NMR spectroscopy and 141 
 
x-ray crystallographic solutions. They identified the region consisting of 120 amino acids 
located in cytoplasmic domain of plexin-B1 that direct binds to Rac1, Rnd1, and RhoD 
(Tong et al., 2007). Previously my group colleague Dr. Oscar Wong has demonstrated 
that mutant plexin-B1 T5714C has lost its binding ability to Rac1 GTPase. This suggests 
that  mutation  of  plexin-B1  results  in  conformation  change  in  its  cytoplasmic  region 
responsible  for  small  GTPase  binding.  Combining  these  facts  and  findings,  I 
hypothesized that the mutations of plexin-B1 might also affect its interaction with RhoD, 
the other small GTPase which is reported to interact with plexin-B1. I generated GST-
fused cyto-plexin-B1 wildtype/mutants proteins and performed GST-pull down assay to 
study if the interaction between plexin-B1 and RhoD was altered by plexin-B1 mutations. 
 
6.2 Results 
6.2.1 Interaction between RhoD and full length plexin-B1 
  Plasmids  encoding  dominant  negative  or  constitutively  active  forms  of  RhoD 
were introduced to HEK293 cells by Lipofectamine transfection. The amount of DNA for 
each  well  of  six-well  plates  is  indicated  in  Figure  6.1.A.  Myc-tagged  Rac  L61/N17 
plasmids were used as positive control for gradient increasing expressions of myc-tagged 
protein in HEK293 cells. The upper panel of Figure 6.1.A shows that myc-tagged RhoD 
T31K  is  26  kDa  and  myc-tagged  RhoD  G26V  is  22  kDa  as  expected  (personal 
communication with Dr. Endo). At a low DNA input at transfection, the expression of 
RhoD T31K or G26V is not detectable at a short exposure time (lanes 1, 2, 4 and 5). The 142 
 
lower panel of Figure 6.1.A illustrates the expression of RhoD T31K/G26V and plexin-
B1 in HEK293 cells co-transfected with these two plasmids. The DNA amounts labeled 
in the figure indicates the quantity of plasmids per transfection for each well of 6-well 
plates. As shown in the figure, the transfection efficiency of plasmid encoding RhoD 
T31K  is  lower  than  that  of  RhoD  G26V,  given  the  same  transfection  conditions. 
According to these results, the optimal ratio of plasmids for transfection was determined. 
  As implied by Tong et al. RhoD interacts with the cytoplasmic region of plexin-
B1 at the same site as that to which Rac1 binds to (Tong et al., 2007). Therefore HEK293 
cells  were  co-transfected  with  plexin-B1  and  RhoD  T31K/G26V  and 
immunoprecipitation  was  carried  out  to  study  the  interaction  between  RhoD  and  full 
length of plexin-B1. There are no positive bands indicating the interaction between full 
length plexin-B1 and either active or inactive form of RhoD in the blots. 
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Figure 6.1 Interaction between RhoD and full length plexin-B1. (A)
HEK293 cells were co-transfected with different quantities of plasmid DNA
encoding constitutively negative (T31K) or active (G26V) RhoD and lysates
were analyzed by Western-blotting. Lower panel shows the titration of DNA
for transfection when co-expressing RhoD T31K/G26V and plexin-B1. Cells
expressing myc-Rac were used as a relative indicator of myc expression. (B)
HEK293 cells were co-expressed RhoD T31K/G26V and plexin-B1/pcDNA3.
Lysates were immunoprecipitated with anti-VSV antibody and probed with
anti-myc antibody to investigate the binding between RhoD and plexin-B1.
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6.2.2 Interaction between RhoD and cyto-plexin-B1 wildtype/mutants 
  Since I could not manage to get positive results in immunoprecipitation assay 
aiming to investigate the interaction between full length plexin-B1 and RhoD, I used 
cytoplasmic plexin-B1 as an alternative to investigate the binding of RhoD and plexin-B1. 
Expression of GST fusion proteins of the cytoplasmic plexin-B1 wildtype/mutants were 
induced in BL21 bacterial cells. The fusion proteins were then extracted and purified by 
incubation with glutathione sepharose 4B matrix. Figure 6.2.A shows the coomassie blue 
staining results of GST fusion proteins before GST purification and of the supernatant 
after purification. All the lanes of the figure were labeled by the name of the plasmid with 
which the BL21 cells were transformed. A control was set as BL21 cells transformed 
with pGEX cyto-plexin-B1 without inducer IPTG. During the GST purification step, only 
GST fusion protein binds to the matrix. Figure 6.2.B illustrates the yield of purified GST 
fusion protein of cytoplasmic plexin-B1 wildtype/mutants. Clear blue bands at the size of 
80 are the GST-fused protein products. There is no equivalent band in GST control which 
originated from cells transformed with pGEX4T3. In the control without IPTG inducer 
there is a very weak band indicating that there was a leak of non-specific induction of 
GST protein during the process. However, this faint band provides evidence of the good 
yield of specific GST fusion protein. 
  I then incubated the GST fusion protein of cyto-plexin-B1 wildtype/mutants with 
lysates  from  HEK293  expressing  either  dominant  negative  RhoD  (T31K)  or 
constitutively active RhoD (G26V). A GST pull-down assay revealed that there is no 
interaction between plexin-B1 with RhoD T31K that encodes inactive form of RhoD 145 
 
(Figure  6.3).  Plexin-B1  binds  to  the  active  form  of  RhoD  and  further  more  mutants 
A5359G and A5653G exhibit an increased binding capability to active RhoD compared 
with  cytoplasmic  plexin-B1  wildtype.  Mutant  T5714C  also  shows  increased  binding; 
though to a lesser extent relative to the other mutants. These results provide evidence that 
mutated forms of plexin-B1 have an increased binding affinity to active RhoD. 146 
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Figure 6.2 Coomassie blue staining of GST-fused products. Vectors encoding
cytoplasmic portion of plexin-B1 wildtype/mutants were introduced to BL21 cells
and GST fusion proteins were induced by adding IPTG. Cells were lysed and
lysates were resolved by SDS-PAGE and followed by Coomassie blue staining.
(A) Cell lysates before purification with Glutathione sepharose 4B beads and after
GST purification were visulized by electrophoreses for quality check. (B) 5 µl of
GST-purified protein matrix was resolved by SDS-PAGE.
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Figure 6.3 Interaction between RhoD and cyto plexin-B1
wildtype/mutants. GST fusion protein of cytoplasmic plexin-B1
wildtype/mutants were induced in E. coli bacterial cells and GST pull-down
assay was performed with HEK293 lysates expressing constitutively inactive
(T31) or active (G26) RhoD. Mutants A5359G and A5653G demonstrated
increased binding ability to active RhoD (G26) compared with wildtype cyto-
plexin-B1, whereas mutant T5714C exhibited a lesser extent of elevated
ability. This is representative of three repeats.
myc-RhoD G26
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6.3 Discussion 
  Previously my group member Dr. Oscar Wong has found that plexin-B1 mutant 
T5714C  has  lost  the  binding  affinity  to  active  Rac.  This  consequently  results  in  the 
inhibition of Rac-dependent plexin-B1 trafficking to the cell surface and loss of inhibition 
of lamellipodia formation (Geewan Wong, The effects of prostate cancer-related plexin-
B1 mutations on protein function, Thesis submitted in 2008, University College London). 
Given the evidence that the region of plexin-B1 for Rac binding is the same site as for 
RhoD interaction, I carried on the research on the effects of plexin-B1 mutation on RhoD 
binding. Using full-length plexin-B1, I did not mange to get positive result of interaction 
between plexin-B1 wildtype and RhoD. The same problem happened with Dr. Wong 
when he was dealing with full-length plexin-B1/Rac interaction assay. The suggested 
explanation for this failure to pull down small Rho GTPases with full-length plexin-B1 
might be the massive size of the full-length plexin-B1 protein (300 kDa). This may make 
the yield of immunoprecipitated RhoD or Rac too low to be detected. 
  By  using  GST  fusion  protein  of  cytoplasmic  plexin-B1  I  have  successfully 
demonstrated  that  plexin-B1  wildtype  binds  to  RhoD,  and  this  is  consistent  to  the 
spectroscopy  and  x-ray  crystallography  results  by  Tong  et.  al.  (Tong  et  al.,  2007). 
However, Tong did not indicate if the binding between plexin-B1 and RhoD GDPase is 
GTP-dependent. In this chapter, I have been the first to show that plexin-B1 specifically 
binds  to  RhoD  GTPase  but  not  RhoD  GDPase.  In  contrast  to  the  finding  of  loss  of 
binding function of plexin-B1 mutants to Rac, the mutations confer a gain of binding 
function  of  plexin-B1  to  RhoD.  Mutated  forms  of  plexin-B1  demonstrate  stronger 149 
 
binding affinity to RhoD G26V than wildtype cyto-plexin-B1 does. In Chapter 5 it is 
presented that cells over-expressing mutated forms of plexin-B1 demonstrate increased 
migration ability compared with cells with plexin-B1 wildtype. Combining these findings, 
increased RhoD GTPase binding is correlated to increased migration ability. RhoD is a 
member of the Rho GTPase subfamily but it possesses unique functions among the Rho 
family.  Over-expression  of  constitutively  active  RhoD  disassembles  stress  fibers  and 
focal adhesions, resulting in decreased cell migration in fibroblasts (Tsubakimoto et al., 
1999). It is likely that by binding to RhoD GTPase, wildtype plexin-B1 sequesters active 
RhoD  and  inhibits  the  suppressive  effect  on  migration  by  RhoD.  Mutated  forms  of 
plexin-B1 exhibit stronger binding affinity to RhoD, suggesting that plexin-B1 mutants 
sequester  more  RhoD  than  the  wildtype  does  and  consequently  lessen  the  inhibitory 
effect of RhoD on migration to a greater extent. Therefore, cells over-expressing mutated 
forms  of  plexin-B1  demonstrate  higher  motility  than  cells  over-expressing  wildtype 
plexin-B1.  In  this  way  expression  of  mutated  forms  of  plexin-B1  may  increase  the 
motility of cells. 
  Zanata et al. has reported the antagonistic effects of Rnd1 and RhoD GTPases on 
Sema3A-induced cytoskeletal collapse (Zanata et al., 2002). Both Rnd1 and RhoD bind 
to the cytoplasmic domain of plexin-A1, which is the receptor for Sema3A. Sema3A 
induces  cytoskeletal  collapse  in  a  Rnd1-dependent  way.  RhoD  blocks  this  Rnd1-
dependent  Sema3A-induced  collapse  (Zanata  et  al.,  2002).  Given  the  fact  that  the 
cytoplasmic domain of plexins is highly concerved among all the members, it is possible 
that binding of RhoD to plexin-B1 antagonizes Rnd-induced collapse. Our group member, 
Dr. Tharani  Nitkunan, has  revealed that cells  expressing mutated forms  of plexin-B1 150 
 
exhibit  decreased  Sema4D-induced  cytoskeletal  collapse  compared  with  the  cells 
expressing wildtype. This phenotype of the mutants is correlated with increased binding 
affinity to RhoD GTPase as demonstrated in this chapter. Taken Zanata’s theory and our 
findings, we propose the model that RhoD mediates Sema4D/plexin-B1 signalling by 
antagonizing Rnd. The Sema4D induced R-Ras GAP activity of plexin-B1 is mediated by 
Rnd. Binding of RhoD to wildtype plexin-B1 antagonizes Rnd and results in a decrease 
in Rnd-mediated R-Ras GAP activity. Mutated forms of plexin-B1 couple more RhoD 
GTPase relative to wildtype plexin-B1 and have increased antagonism to Rnd, resulting 
in loss of R-Ras GAP activity and block of Rnd1-dependent cell collapse induced by 
Sema4D.  Zanata  did  not  show  if  Rnd1  and  RhoD  compete  for  plexin-A1  binding. 
Previously our group has shown that mutants A5359G and A5653G bind to Rnd, and 
mutant T5714C has lost the ability to bind to Rnd1 (Wong et al., 2007). However mutant 
T5714C has only a small increase in RhoD binding compared to mutants A5359G and 
A5653G. This suggests that Rnd and RhoD may not compete for plexin-B1 binding. This 
should be confirmed by further analysis if given more time. The mutated site for mutant 
T5714C is in the Rac-binding domain of plexin-B1, while mutants A5359G and A5653G 
are outside of this domain (Tong et al., 2008). Mutant T5714C has lost Rac binding 
ability, whereas the other two mutants have gained ability to bind to RhoD. Therefore the 
mutated region of mutants A5359G and A5653G are more important in RhoD binding. 
Mutants A5359G and A5653G possibly result in conformation change, suggested by Dr. 
Matthias Buck (personal communication). This  conformation change may explain the 
increased RhoD binding ability.  151 
 
RhoD is unique among Rho family members that it regulates the motility of early 
endosomes  (Murphy  et  al.,  1996).  The  effectors  of  RhoD  have  not  been  extensively 
studied. hDia2C protein is the first identified effector for RhoD and it induces alignment 
of  early  endosomes  along  actin  filaments  and  inhibits  endosome  motility  in  a  c-Src 
kinase-dependent  way  (Gasman  et  al.,  2003).  Src  is  necessary  for  Sema4D-induced 
Akt/PI3K pathway activation in endothelial cells. These together may imply that Src may 
crosslink the RhoD and Akt/PI3K pathways through Sema4D/plexin-B1 activation. On 
the  other  side,  this  hypothesis  is  likely  dependent  on  cell  types  since  Akt  pathway 
activation through Sema4D is only reported in endothelial cells. If given more time, I 
would  further  explore  the  downstream  of  RhoD  in  context  with  Sema4D/plexin-B1 
signaling. To determine the effects of increased RhoD binding observed in the mutants, 
inhibition of RhoD activity assays may be performed to further investigate cell functions. 
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7.1 Significance of this study 
  Our group has been the first to report plexin-B1 mutations in prostate cancer. Of 
all the mutated forms identified in both clinical samples and prostate cancer cell lines, we 
have been focusing on mutants A5359G, A5653G, and T5714C and have revealed that 
cells  expressing  these  mutated  forms  of  plexin-B1  exhibit  more  metastatic  features 
compared with cells expressing wildtype plexin-B1 (Wong et al., 2007). In this study I 
continued the study on molecular characterization of plexin-B1 mutation and explored 
how these mutated forms affect cell signalling and cell functions. My studies on tyrosine 
kinases ErbB-2, Met and small GTPase RhoD completed the blank spaces of Table 1.1 in 
Chapter 1 and are summarized in Table 7.1. 
Table 7.1 Protein function changes of the plexin-B1 mutations relative to wildtype 
  Rac 
binding 
Rnd 
binding 
R-Ras 
binding 
RhoD 
binding 
ErbB-2 
binding 
Met 
binding 
PDZ-RhoGEF 
binding 
wt  binds  binds  binds  binds  binds  binds  binds 
A5359G  reduced  binds  lost  increased  binds  binds  binds 
A5653G  reduced  binds  lost  increased  binds  binds  binds 
T5714C  lost  lost  lost  increased  binds  binds  binds 
 
Due  to  the  lack  of  intrinsic  tyrosine  kinase  activity  of  plexin-B1,  the  signal 
transduction pathways initiated by Sema4D/plexin-B1 involves extrinsic tyrosine kinases. 
Several  tyrosine  kinases  such  as  Met,  ErbB2,  and  PI3K/Akt  have  been  extensively 
studied  in  Sema4D/plexin-B1  signalling  and  play  crucial  roles  either  upstream  or 
downstream of plexin-B1. Whether mutations of plexin-B1 have any effect on tyrosine 154 
 
kinase-regulated plexin-B1 signalling was not previously known. My study on tyrosine 
kinases has unveiled this aspect. Met and ErbB-2 are the two main receptor tyrosine 
kinases  that  interact  with  plexin-B1  and  regulate  cell  movement.  All  three  mutants, 
A5359G, A5653G, and T5714C bind to either Met or ErbB-2 to the same extend as 
wildtype  plexin-B1  does.  Therefore  mutations  located  in  the  cytoplasmic  portion  of 
plexin-B1  do  not  change  the  protein’s  binding  ability  to  Met  or  ErbB-2  through  the 
extracellular domain. 
The effects of Met and ErbB-2 on Sema4D/plexin-B1-regulated cell motility have 
been contradictory according to the reports of different research groups. Swiercz et al. 
have shown that treatment of breast cancer cells co-expressing plexin-B1 and ErbB-2 
with Sema4D results in increased migration, whereas treatment of cells co-expressing 
plexin-B1 and Met results in decreased migration (Swiercz et al., 2008). Other groups 
have shown that the interaction of Met and plexin-B1 enhances migration (Giordano et al., 
2002). The study on Met/plexin-B1 and ErbB2/plexin-B1 using prostate cancer cell lines 
LNCaP and PC3 show consistent results with Swiercz’s. My group leader Dr. Williamson 
has demonstrated Sema4D increases cell motility in the LNCaP cell line. I have found 
that Sema4D decreases cell motility in PC3 cells. Western-blotting analysis shows that 
these two cell lines exhibit special patterns of Met/ErbB-2 expression that fit the theory 
of  the  reciprocal  roles  of  Met  and  ErbB-2  on  Sema4D/plexin-B1-regulated  motility 
(Swiercz et al., 2008). LNCaP expresses ErbB-2 but not Met, while PC3 expresses Met 
and  a  relatively  low  level  of  ErbB-2.  These  findings  suggest  that  the  cell  motility 
response stimulated by Sema4D through endogenous plexin-B1 in prostate cancer cells 
depends  on  the  stoichiometry  of  plexin-B1,  ErbB-2  and  Met.  Sema4D  could  initiate 155 
 
diverse cell responses depending on the composition of the heteromultimeric receptor 
complexes formed by plexin-B1 and other receptor tyrosine kinases. Further evidence for 
a link between the identity of the receptor tyrosine kinase with which plexin-B1 couples 
and the response to Sema4D could be provided by screening other prostate cancer cell 
lines for Met/ErbB-2 expression and for increased or decreased Sema4D-induced motility. 
To determine if the opposite effects of Sema4D on PC3 and LNCaP are due to plexin-B1 
signalling via Met and  ErbB-2 respectively, expression of these two tyrosine kinases 
could be reversed. This would be achieved by reducing ErbB-2 activity with inhibitors or 
siRNA in conjunction with exogenous expression of Met in LNCaP. In a similar way, 
Met  could  be  inhibited  and  ErbB-2  over-expressed  in  PC3.  Motility  in  response  to 
Sema4D could then be assayed. It remains unclear how the RhoA activity downstream of 
Sema4D/plexin-B1 signalling is regulated by ErbB-2 and Met in prostate cancer cell lines. 
In addition, it is not clear whether the mutated forms of plexin-B1 have any impact on 
ErbB-2/Met-regulated RhoA activation in prostate cancer  cells.  The answers to  these 
questions will help with the characterization of the molecular mechanism underlying the 
contribution of plexin-B1 mutations to prostate cancer progression. After I had completed 
my  work,  Swiercz  et  al.  have  newly  found  that  ErbB-2  phosphorylates  plexin-B1  in 
response  to  Sema4D  at  different  tyrosine  residues  from  Met,  leading  to  binding  of 
phospholipase Cγ (PLCγ) to plexin-B1 and activation of PDZ-RhoGEF (Swiercz et al., 
2009). The difference in the position of the phosphorylation sites in plexin-B1 that are 
phosphorylated by ErbB-2 and Met, and presumably the different adaptor proteins which 
bind  to  these  phosphorylated  tyrosines,  may  explain  the  opposite  effects  on  RhoA 
regulation downstream of Sema4D/plexin-B1. 156 
 
 PI3K/Akt  and  MAPK  pathways  are  two  important  pathways  that  have  been 
extensively studied in cancer and other human diseases. Both of the pathways have been 
implicated  in  Sema4D/plexin-B1  signalling.  Different  research  groups  have  reported 
contradictory  findings  for  the  response  of  PI3K/Akt  under  the  regulation  of 
Sema4D/plexin-B1 (Basile et al., 2005;  Ito et  al., 2006; Swiercz et al., 2004). These 
opposite results of PI3K/Akt phosphorylation status in response to Sema4D/plexin-B1 
signalling may depend on different cell types and the corresponding cellular context. My 
study on PI3K/Akt and MAPK aimed to identify if mutated forms of plexin-B1 have any 
effect on activation of these kinases compared to wildtype. Ito et al. has reported that 
PI3K/Akt  is  downstream  of  plexin-B1/Rnd1-regulated  R-Ras  GAP  activity  and  is 
decreased in activity in response to Sema4D (Ito et al., 2006). Our group has previously 
found that all the three mutants A5359G, A5653G, and T5714C have lost the binding 
ability to R-Ras and the R-Ras GAP activity. Combining these findings, it is possible that 
plexin-B1  mutants  may  affect  downstream  PI3K/Akt  activity  in  response  to  Sema4D 
relative to wildtype. Swiercz et al. also found that Sema4D/plexin-B1 signaling via ErbB-
2 increased Akt phosphorylation (Swiercz et al., 2004). However, no alteration in Akt 
phosphorylation  has  been  observed  under  the  effect  of  Sema4D  in  HEK293  cells 
expressing plexin-B1 wildtype/mutants in this study. Plexin-B1 wildtype and mutants do 
not  show  any  differences  in  Akt  phosphorylation  in  response  to  Sema4D.  Cells 
expressing mutant plexin-B1 do not show any difference in the magnitude of activation 
of MEK and Erk. However, any change in phosphorylation of these proteins in response 
to Sema4D may have been masked by phosphorylation resulting from treatment with the 
vehicle solution for Sema4D. As described in Chapter 4, many efforts have been made in 157 
 
order to get rid of the masking effects on MAPK activation. The complexity and number 
of different signalling pathways that result in activation of PI3K/Akt and MAPK also 
increases the difficulty of revealing the molecular linkage between Sema4D/plexin-B1 
and PI3K/Akt and MAPK pathways. It is possible that plexin-B1 together with many 
other  proteins  mediate  PI3K/Akt  and  MAPK  pathways  and  the  mechanism  of  this 
remains to be elucidated. 
Small GTPases such as Rnd1 and Rac1 are the other class of proteins that are 
critically involved in plexin-B1 signal transduction. Plexin-B1 sequesters Rac from PAK 
by interaction with Rac. Rnd1 is required for plexin-B1-mediated R-Ras GAP activity. 
Previously our group have reported that mutant T5714C has lost the ability to bind to 
Rnd1 and Rac1 compared to the wildtype plexin-B1. Although mutants A5359G and 
A5653G do not show any alteration in binding to Rnd1, these two mutated forms have 
decreased ability of sequestering active Rac1. Since Rac, Rnd and RhoD bind to plexin-
B1 at the same region between C1 and C2 domains according to Tong et al., it was 
though possible that mutated forms  of plexin-B1 affect  RhoD binding.  I have newly 
confirmed  the  binding  of  wildtype  plexin-B1  and  active  RhoD  using  an 
immunoprecipitation approach, and this finding is consistent with that of Tong using 
crystallographic and structural solutions. All the three mutants exhibit increased binding 
ability towards active RhoD. Mutants A5359G and A5653G exhibit stronger interaction 
with RhoD than mutant T5714C does. Combining these results, we could come to the 
conclusion that the three site mutations within the small GTPase binding motif of plexin-
B1  severely  alter  the  association  between  small  GTPases  and  plexin-B1.  My  group 
members and I have performed cell invasion assays and migration assays on cells stably 158 
 
expressing plexin-B1 wildtype/mutants and have found that mutants A5359G, A5653G, 
and  T5714C  show  increased  motility  compared  to  wildtype.  Given  that  mutations  of 
plexin-B1 are frequent in prostate cancer metastases, the three mutants are very likely 
correlated with tumor progression. Our findings on the altered binding ability to Rac, Rnd 
and RhoD of plexin-B1 mutants provide possible molecular mechanism responsible for 
the  increased  metastatic  features.  The  proposed  model  of  how  RhoD  contributes  to 
plexin-B1-mediated  cell  motility  has  been  discussed  in  Chapter  6.  Binding  of  active 
RhoD to plexin-B1 may inhibit the suppressive effect of RhoD on cell motility. The 
interaction of plexin-B1 and RhoD also antagonizes the Rnd1-mediated cell collapse, 
leading  to  increased  cell  motility.  Although  this  proposed  theory  needs  to  be  further 
tested,  my  project  together  with  our  group  members’  findings,  establish  the  basic 
molecular  characterization  of  the  role  of  plexin-B1  mutations  on  prostate  cancer 
progression.  The detailed discussion of how plexin-B1 mutations contribute to cancer 
invasion and metastasis via those affected pathways will be introduced in next section of 
this chapter. 
 
7.2 Contribution of plexin-B1 mutations to the progression of prostate cancer 
  Based on the knowledge on Sema4D/plexin-B1 signalling pathways, the network 
of plexin-B1 is summarized into a diagram as shown in Figure 1.5 in Chapter 1. Plexin-
B1 couples oncogene ErbB-2 and activates ErbB-2 in response to Sema4D, which in turn 
phosphorylates plexin-B1 and activates RhoA, resulting in an increase in cell motility and 
promotion of the invasive phenotype. On the other side, plexin-B1 sequesters Rac1 and 159 
 
inactivates  R-Ras  GTP,  resulting  in  decreased  adhesion  and  increased  cell  collapse. 
Interaction  of  plexin-B1  and  RhoD  suppresses  the  inhibitory  effect  of  RhoD  on  cell 
migration. RhoD binding also antogonizes Rnd and inhibits plexin-B1/Rnd-mediated cell 
collapse induced by Sema4D. These pathways work together to regulate cell movement 
and the net effect of these pathways determines the cells motility. Plexin-B1 mutations 
alter the way that the plexin-B1 protein functions and the cumulative effect of mutations 
on the various affected pathways is manifested as an increase in metastatic characteristics. 
Given the findings of our research work, we propose a model of how prostate cancer-
related mutations of plexin-B1 contribute to the progression of prostate cancer (Figure 
7.1). The mutations may selectively inhibit plexin-B1 inhibitory pathways (via R-Ras, 
Rac  and  RhoD)  while  retaining  activation  of  promoting  pathways  (ErbB-2,  Met), 
resulting in an increase in adhesion, motility and invasion relative to wildtype plexin-B1. 
In addition to the high frequency of somatic missense mutations in the plexin-B1 gene in 
both  localized  and  metastatic  prostate  cancer,  we  also  observed  over-expression  of 
plexin-B1 protein in primary prostate cancers. Tumor progression occurs by enhanced 
Sema4D/plexin-B1  signalling  via  ErbB-2  for  wildtype  and  mutant  plexin-B1.  I  have 
shown that plexin-B1 mutants retain the ability of ErbB2-mediated cell motility. On top 
of this, plexin-B1 mutants do not bind and sequester Rac and has lost R-Ras GAP activity, 
leading to a loss of inhibitory effects on metastatic phenotypes. Expression of mutated 
forms of plexin-B1 results in increased adhesion and decreased cell collapse. In addition 
plexin-B1  mutants  enhance  the  binding  to  RhoD,  resulting  in  suppression  on  the 
inhibitory effect of RhoD on cell migration. The increased binding ability of mutants to 
RhoD may also release the suppressive effect of Rnd-mediated R-Ras GAP, leading to 160 
 
reduced  cell  collapse.  The  cumulative  effects  result  in  a  net  increase  in  motility  by 
mutants. Therefore, mutations may confer a gain of metastatic phenotypes to the cell 
through inactivation of inhibitory pathways on cell motility, leading to tumor progression. 
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Figure 7.1 Proposed model of how plexin-B1 mutations affect cell signaling and
contribute to increased cell motility. Sema4D/plexin-B1 transduces its signal through
coupling with other proteins and forms a complex signaling network. Mutated forms of
plexin-B1 retain the ability to bind to ErbB-2, Met and PDZ-RhoGEF which positively
regulate cell migration. The mutations inhibit Rac, Rnd1 and R-Ras binding and R-Ras
GAP activity. The mutated forms of plexin-B1 have therefore lost the ability to sequester
Rac, leading to increased lamellipodia formation and cell spreading. In addition, the
plexin-B1 mutants no longer bind to R-Ras and have lost the R-Ras GAP activity. My
results have shown that the plexin-B1 mutants have increased RhoD binding ability.
RhoD binding may antagonize the plexin-B1/Rnd-induced R-Ras GAP activity, resulting
in loss of R-Ras inhibition and subsequent increased cell motility relative to the
wildtype. The net result is an increase in motility.
Binding
  Loss of binding
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7.3 Future work 
  A high frequency of mutations in the plexin-B1 gene has been found in prostate 
cancer metastasis. Some of the mutations are also present in other tumors such as breast 
cancer. These findings suggest that plexin-B1 may be a potential oncogene. Our research 
on three mutants A5359G, A5653G and T5714C has lead to a proposed model of how 
plexin-B1 mutations contribute to cancer progression. More work is needed to test this 
model.  So  far  we  mainly  used  non-prostate  cells  to  determine  if  the  mutations  were 
functionally significant. However response to Sema4D is highly dependent on cell types 
and cellular context. Therefore, prostate cancer cell lines should be applied to determine 
the effect of mutant/wildtype plexin-B1 expression in response to Sema4D. During the 
time  this  thesis  was  drafted,  our  group  has  found  plexin-B1  may  play  a  role  in  cell 
proliferation.  LNCaP  cells  treated  with  siRNA  targeting  at  plexin-B1  demonstrated 
slower proliferation rate than the control (personal communication with Dr. Williamson). 
These preliminary results suggest that plexin-B1 may also control cell proliferation in 
additional to its role in cell movement. In our proposed model, RhoD may increase cell 
motility  and  suppress  cell  collapse  through  inhibiting  the  Rnd-induced  R-Ras  GAP 
activity. Further evidence is needed to confirm that the loss of R-Ras GAP activity in the 
three mutants is partly due to elevated RhoD binding to plexin-B1. To further test this, 
we could use siRNA to inhibit RhoD expression to investigate if the R-Ras GAP activity 
in  plexin-B1 wildtype  expressing cells  is  higher than the  control.  In  cells  expressing 
plexin-B1 mutants, we could inhibit RhoD expression to study if suppression of RhoD 
restores the R-Ras GAP activity in mutants A5359G and A5653G. There should be no 163 
 
change for mutant T5714C as it does not bind Rnd and has lost the R-Ras GAP activity 
completely. 
My findings on cell lines have revealed the role of plexin-B1 mutations on the 
metastatic  phenotype  in  vitro.  It  is  also  important  to  know  the  functions  of 
wildtype/mutant  plexin-B1  in  vivo.  Xenografts  of  prostate  cancer  cells  expressing 
wildtype/mutant plexin-B1 and prostate cancer cell lines in which plexin-B1 expression 
has  been  knocked  out,  could  be  applied  to  determine  the  role  of  plexin-B1  and  its 
mutations  in  tumorigenicity. Transgenic mouse  models  in  which mutant  plexin-B1 is 
expressed in prostate only may provide insight on the effects of mutations on the process 
of metastasis of prostate cancer.  To achieve this, a transgenic mouse could be generated 
with mutant plexin-B1 cDNA downstream of a Cre-inducible promoter. Crossing this 
mouse with a Probascin-Cre transgenic mouse would generate offspring in which mutant 
plexin-B1 is expressed in prostate epithelial cells only. This would be a good model to 
fully explore the promoting role of plexin-B1 mutations in prostate cancer development. 
Although there is much work to be done in further characterizing the significance of 
plexin-B1 mutations in prostate cancer progression, our research work has revealed the 
role of plexin-B1 in cancer metastasis and identified it as a potential therapeutic target in 
the future. 
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APPENDIX 1 
 
pEF-BOS/Myc vector
Plasmids DNA encoding pEF-BOS/Myc-RhoD (G26V) and pEF-BOS/Myc-Rhod
(T31K) were gift from Professor Endo (Chiba University). cDNA encoding
G26V/T31K was subcloned into the vector at the HindIII and EcorRI sites. The
plasmid is ampicillin resistant. (The figure was adapted from Professor Endo’s
information.)
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Plasmid DNA encoding vsv-tagged plexin-B1 was a gift from Dr. Tamagnone
(University of Torino School of Medicine, Italy). cDNA encoding VSV-tagged
plexin-B1 (5.6 kb) was subcloned into pcDNA3 vector at the Hind III and EcoR I
sites. VSV was tagged at the N-terminal of plexin-B1. The plasmid is ampicillin
resistant. (The figure was adapted from Invitrogen data sheet.)
pcDNA3 vector
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Plasmid DNA encoding GST-fused cyto-plexin-B1 wildtype/mutants were
constructed with pGEX-4T-3 vector. cDNA encoding the cytoplasmic region of
plexin-B1 (aa 1512-2135) was subcloned into the vector at the Sal I and Xho I
sites. The plasmid is ampicillin resistant. (The picture was adapted from Amersham
data sheet.)
PGEX-4T-3 vector
 167 
 
 
 
Plasmid DNA encoding ErbB-2 was a gift from Dr. Swiercz (University of
Hedelberg, Germany). Full length ErbB-2 was subcloned into pLNCX2 vector. The
plasmid is ampicillin resistant.
pLNCX2 vector
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Met plasmid 
The plasmid encoding full length Met was a gift from Dr. Tamagnone and was labled as 
PRRL2SinPPThCMVMCSpre. It was specifically designed vector by his group and was 
compatible for lentivirus infection as well. 
 169 
 
APPENDIX 2 
 
List of reagents and Kits 
Name  Company  Catalogue no. 
Albumin from bovine serum  Sigma-Aldrich  A8806 
Amicon Centricon YM-10  Millipore  4205 
Benzonase nuclease  Sigma-Aldrich  E1014-25K 
CelLytic B cell lysis reagent  Sigma-Aldrich  B7435-500 
Complete mini protease cocktail  Roche  04693124001 
Coomassie  Plus-the  better  bradford  assay 
reagent 
Pierce  23238 
Costar transwells 0.8µ m  Sigma-Aldrich  CLS 3422 
DNase I  Sigma-Aldrich  D4527-40KU 
Fetal bovine serum ultra-low IgG  Invitrogen  16250-086 
Fibronection (0.1%) from human  Sigma-Aldrich  F0895 
Full-range rainbow molecular weight markers  Amersham  RPN800E 
Glutathione Sepharose 4B  Amersham  17-0756-01 
Lipofectamine 2000 Transfection reagent  Invitrogen  11668-019 
LPA sodium salt  Sigma-Aldrich  L7260 
Modified lowry protein assay kit  Pierce  23240 
PBS,pH 7.4 sterile  Invitrogen  10010 
Protein A agarose  Invitrogen  15918-014 
Redipack GST purification module  GE healthcare  27-4570-02 
Recombinant  human  semaphorin  3A-Fc 
chimera 
R&D systems  1250-S3 
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APPENDIX 3 
Numbers of PC3 cells migrated in migration assays for Figure 4.6 
  control  Sema4D 
Experiment 1  2908  2816 
Experiment 2  1972  1813 
Experiment 3  1331  1139 
Experiment 4  1917  1452 
Experiment 5  1375  912 
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Numbers of cells migrated in migration assays for Figure 5.1 
Experiment1 
  control  Sema4D 
Vector  333  342 
Wildtype  132  124 
A5359G  1270  1345 
A5653G  1219  1300 
T5714C  332  311 
 
Experiment 2 
  control  Sema4D 
Vector  466  431 
Wildtype  165  158 
A5359G  1728  1242 
A5653G  1785  1789 
T5714C  647  665 
 
Experiment 3 
  control  Sema4D 
Vector  406  311 
Wildtype  216  181 
A5359G  1799  1350 
A5653G  1765  1584 
T5714C  335  363 
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